UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
FOR ANNUAL AND TRANSITION REPORTS
PURSUANT TO SECTIONS 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
(Mark One)
[X] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934 for the year ended December 31, 2003 or
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the transition period from ________ to ________.
Commission file Number 0-6333
HYDRON TECHNOLOGIES, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
New York 13-1574215
------------------------------- -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
2201 West Sample Road, Building 9, Suite 7B, Pompano Beach, FL 33073
----------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (954) 861-6400
--------------
Securities registered pursuant to Section 12(b) of the Act: None
----
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $.01 per share
--------------------------------------
(Title of Class)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. YES [X] NO [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein and will not be contained, to
the best of the Registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any other
amendment to this Form 10-K. [ ]
Indicate by check mark whether the registrant is an accelerated filer
(as defined in Exchange Act Rule 12b-2). YES [ ] NO [X]
The aggregate market value of the voting stock held by non-affiliates
of the Registrant was $4,415,213 based upon the closing price of $0.65 on March
31, 2004.
Number of shares of Common Stock outstanding as of April 7, 2004: 9,260,136.
Documents Incorporated by Reference: None
----
TABLE OF CONTENTS PAGE
Part I
Item 1. Business 3
Item 2. Properties 11
Item 3. Legal Proceedings 12
Item 4. Submission of Matters to a Vote of Security Holders 12
Part II
Item 5. Market for Registrants Common Equity, Related
Stockholder Matters and Issuer Purchases of
Equity Securities 13
Item 6. Selected Financial Data 16
Item 7. Management's Discussions and Analysis of Financial
Condition and Results of Operations 17
Item 7A. Quantitative and Qualitative Disclosures About
Market Risk 28
Item 8. Financial Statements and Supplemental Data 28
Item 9. Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure 29
Item 9A. Controls and Procedures 29
Part III
Item 10. Directors and Executive Officers of the Registrant 30
Item 11. Executive Compensation 31
Item 12. Security Ownership of Certain Beneficial Owners and
Management and Related Stockholder Matters 33
Item 13. Certain Relationships and Related Transactions 34
Part IV
Item 14. Principal Accountant Fees and Services 35
Item 15. Exhibits, Financial Statement Schedules and Reports
on Form 8-K 36
Report of Independent Certified Public Accountants 39
Financial Statements: Balance Sheets - December 31, 2003 and 2002 40
Statements of Operations
Years ended December 31, 2003, 2002, and 2001 41
Statements of Changes in Shareholders'
Equity for the Years ended December 31, 2003, 2002, and 2001 42
Statements of Cash Flow
Years ended December 31, 2003, 2002, and 2001 43
Notes to Financial Statements 44
Consent of Independent Certified Public Accountant 58
Signatures 59
Certification of Chief Officers Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 and Item 307 of Regulation S-K 60
Certification Pursuant to 18 U.S.C, Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 63
2
PART I
Item 1. Business
Introduction
Hydron Technologies, Inc. ("the Company"), a New York corporation
organized on January 30, 1948, maintains its principal office at 2201 West
Sample Road, Building 9, Suite 7B, Pompano Beach, Florida 33073 and its
telephone number is (954) 861-6400.
Hydron Technologies, Inc. is conducting research and development into
products and medical applications utilizing its patented tissue oxygenation
technology. The Company's super-oxygenation technology delivers pure oxygen
through the skin to tissue depths considered therapeutic for wound healing and
the maintenance of tissue viability. Hydron's technology utilizes micro-bubbles
of pure oxygen, averaging one micron in diameter, to deliver oxygen deep into
tissue. Using topical application, oxygen can now be targeted at specific
problem areas and delivered into skin and tissue that is not receiving
sufficient oxygen from the bloodstream, essentially oxygenating from the outside
in.
The Company also markets a broad range of consumer and oral health care
products using a moisture-attracting ingredient (the "Hydron(TM) polymer"), a
topical delivery system for active ingredients including pharmaceuticals. The
Company holds U.S. and international patents on, what Management believes is,
the only known cosmetically acceptable method to suspend the Hydron polymer in a
stable emulsion for use in personal care/cosmetic products. The Company is
developing other personal care/cosmetic products for consumers using its
patented technology and would, when appropriate, either seek licensing
arrangements with third parties, or develop and market proprietary products
through its own efforts. Management believes that because of their unique
properties, products that utilize the Hydron polymer have the potential for wide
acceptance in consumer and professional health care markets.
Super-oxygenated Fluids and Compositions
Since August 2000, the Company has been researching and developing a
new technology that provides a method for the delivery of oxygen into the skin
and tissue at depths considered medically therapeutic without the use of the
bloodstream. In November 2003, the Company received patent number 6,649,145 from
the United States Patent and Trademark Office covering this exceptional method
of delivery. Management anticipates that as a result of its continuing research
into tissue oxygenation, the Company's primary focus will be
developing/licensing applications or products based upon this new technology.
Hydron's unique process utilizes an existing technology that infuses
liquid with oxygen at 20+ times normal levels to create a super-oxygenated
liquid filled with micro-bubbles of highly pressurized oxygen. When placed in
contact with the skin, the highly saturated fluid and micro-bubbles are
transferred directly into the skin through osmosis and kinetic diffusion between
cells.
3
Item 1. Business (continued)
Research and development efforts to date have included clinical
testing, in-vitro bacteriological testing, micro-bubble size analysis, packaging
prototypes, and stability testing. Following its successful pre-clinical test at
the University of Massachusetts Medical School, Department of Thoracic Surgery,
the Company commissioned a clinical test on healthy human subjects. This
clinical test produced an average increase in subcutaneous tissue oxygenation of
54%. Management believes that these tests provided the first-ever evidence that
subcutaneous tissue could be oxygenated from the outside in without the use of
high pressure-chamber treatment.
This topically applied oxygenated skin treatment could have numerous
applications in wound healing and anti-aging skincare treatments. Current market
research shows that each year, in the United States alone, medical problems
associated with oxygen deprivation to the skin and tissues can affect over 16
million diabetics, two million burn patients, 600,000 individuals with impaired
circulatory systems and countless other applications, from individuals suffering
with chronic wounds to extending the life of organs for transplant during
transportation. Likewise, medical problems associated with anaerobic bacteria
(i.e. organisms that thrive in the absence of oxygen) such as acne, diaper rash,
post-operative infections and periodontal disease may be reduced or eliminated
by application of this technology.
Oxygen is also an essential factor in aging as the facial skin loses
about 40% of oxygen carrying capacity by age 65 (a factor in diminished collagen
formulation and wrinkling). As a result, anti-aging/wrinkling applications of
this technology may ultimately lead to a new line of skincare applications and
products.
In July 2002, the Company reached an agreement providing the right but
not the obligation for licensing existing micro-bubble machine technology from
Life International Products, Inc. that included issuance of 325,000 shares of
new Hydron stock and future royalty payments if their technology is used. This
will allow Hydron a definitive source of producing micro-bubble liquids that are
required to manufacture future products under Hydron's tissue oxygenation
patent.
On November 14, 2003, the Company completed a non-brokered private
placement to accredited investors of 2,210,000 Units at $.50 per Unit that
raised $1,105,000 for oxygenation technology research. Each Unit is comprised of
one share of Common Stock and one five-year warrant to buy one additional Common
Share at $1.00. Such securities were not registered under the Securities Act of
1933 as amended ("Securities Act"), in reliance on exemptions for private
placements of securities. Directors Richard Banakus and Ronald J. Saul invested
in this offering along with 17 other accredited investors. The proceeds will be
used to advance the testing and development of the Company's oxygenation
technology and support the initial submissions required for FDA (Food and Drug
Administration) approvals.
4
Item 1. Business (continued)
Hydron(TM) Branded Skin Care Products
The Company has been engaged in the development of various consumer
products using Hydron polymers since 1986. The Company's products are designed
to address concerns about aging, and include Hydron(TM) skincare, hair care,
bath and body and sun care. The Company currently has thirty-six individual
products available in the following product lines: skin care (21 products), hair
care (6 products), bath and body (7 products) and sun care (2 products). These
products are also packaged into collections and sold at a more favorable value
than the individual products sold separately. All of the products are available
through the Hydron(TM) Catalog and Web site www.hydron.com ("Catalog").
Management believes that the Company's skin care products are unique
and offer the following competitive benefits: the moisturizers self-adjust to
match the skin's optimal pH balance soon after they are applied to the skin;
they become water-insoluble on the skin's surface, and unlike all other
water-based cremes and lotions, are not removed by the skin's perspiration or
plain water; they are oxygen-permeable, allowing the skin to breathe; they do
not emulsify the skin's natural moisturizing agents, as do conventional cremes
and lotions; and they attract and hold water, creating a cushion of moisture on
the skin's surface that promotes penetration of other beneficial product
ingredients, all while leaving no greasy after-feel.
The Company's products are dermatologist tested and approved for all
skin types. Products for use around the eye area are also ophthalmologist tested
and safe for contact lens wearers. Most of the Company's moisturizing products
are based on the Company's patented emulsion system, which permits the product
ingredients to deliver their intended benefits over an extended period of time
and in a more efficient manner.
Management believes that the Hydron(TM) emulsion system can enhance the
effectiveness of topical over-the-counter medications. The emulsion system is
designed to deposit a polymer film on the skin's surface which has a number of
advantages over traditional lotions: promotes hydration of the outer layer of
skin, improves penetration into the skin's pores, and has good tactility and
flexibility. The Company expects to continue to focus research and development
resources on proprietary technology-based products as determined by Management's
assessment of consumer demand.
The Company discovered that the Hydron(TM) emulsion system also adjusts
pH on the skin to match the pH of the stratum corneum, the skin's surface layer.
It is evident in recent skin research (see Kligman, in "Dry Skin and
Moisturizers, Chemistry and Function", editors Marie Loden and Howard I.
Maibach, CRC Press, New York, p 3-9 2002) that the pH range of the emulsion
system is ideal for contributing to the skin's natural healing process and
enzyme production responsible for rebuilding the skin's lipid barrier. A patent
application was filed February 14, 2002 to cover this technology, which also
applies to a new acne treatment system.
5
Item 1. Business (continued)
Professional Products
The Company has also developed and currently markets a group of Hydron
polymer-based products for dental professionals under the Hydrocryl(TM) brand
name. These include a heat cured material used in the manufacture of dentures,
as well as cold cure kits used in connection with the relining or repairing of
existing Hydrocryl(TM) or conventional acrylic dentures that is necessitated by
the continual changes that occur in the tissue structure of the mouth.
Management believes that the hydrophilic, or moisture attracting properties, of
these Hydron(TM) polymer-based products give them competitive advantages over
conventional acrylic dentures and denture repair kits, which are not
hydrophilic. Sales of Hydrocryl(TM) brand name products were minimal in 2003,
2002, and 2001.
Distribution
The majority of the Company's products are currently sold in the United
States through Hydron direct marketing channels (proprietary Catalog and the
World Wide Web site). The Company also sells its products to private label
customers, television retailers and, to a lesser extent, internationally through
salons and doctors offices.
While in prior years television retail was the primary focus for the
marketing and distribution of the Company's products, Management believes that
the Company's exclusive agreements with television retailers had limited the
marketing opportunities to build its business through additional sales channels.
Under exclusive contracts with television retailers the Company neither
controlled its airtime nor the selling priorities of those television retailers,
effectively handicapping the Company's ability to influence sales trends.
The Company began diversifying away from television retailers in 2001
with continued focus on developing the Catalog business and the addition of a
private label customer to provide additional cash flow. Further, the Company has
been pursuing new international distribution and new products that would
significantly augment Hydron's direct marketing efforts. This development
includes filing a patent in February 2002 on new acne formulas that the Company
believes provides marked performance improvements versus other over-the-counter
products currently on the market.
Catalog Sales - The Company's full color brochure offers personal care products
for sale directly to consumers. The brochure also provides information on new
products, educates consumers on proper skin care and facilitates consumer
re-ordering. The Company sells its products on the World Wide Web and regularly
transmits E-mail broadcasts to its customer base. Catalog sales represents
approximately 80.5% of Hydron's total annual sales in 2003 and 68.5% in 2002.
The Company is continuing to explore new ways to enhance Catalog sales and
operations.
Private Label Contracting - Effective March 1, 2001, the Company entered into an
agreement with Reliv International, Inc ("Reliv") to develop and manufacture a
line of private label skin care products under their brand name, ReversAge(R).
Five products were introduced in August 2001 at a national sales meeting to
6
Item 1. Business (continued)
Reliv's multi-tier marketing distribution network. A sixth new product was
introduced in February 2002. The agreement requires minimum product purchases
and advance payments to cover packaging and design costs. Reliv is a public
company traded on NASDAQ (symbol RELV). Private label sales represented
approximately 4.7% of Hydron's total annual sales in 2003 and 7.8% in 2002.
International - The Company sells product to an Australia-based health and
beauty products distributor for retail salon stores and medical offices in
Australia and New Zealand. The Company also distributes dental products into
Spain and, to a lesser extent, other countries. Although this category is not
significant at this time, Management believes that it will expand with the
introduction of super-oxygenated technology.
Retail - The Company has established minor levels of retail distribution.
Initially, utilizing excess inventory, the Company has sold product on a
limited, promotional basis to several retailers utilizing current packaging
configurations. It is anticipated that any significant retail effort of core
Hydron products would require investment in repackaging.
Research and Development
During the last two years, the Company's research and development
efforts advanced groundbreaking research into oxygenated wound treatments,
healing enhancement, and skin care that may provide anti-aging treatments. Where
possible, the Company may license these technologies to other companies with
expertise in specific applications of the Company's super-oxygenated technology.
Research and development efforts include product formulation, clinical testing,
packaging design and prototypes, extensive product safety and stability testing
conducted by medical professionals, efficacy studies to support product claims,
and consumer research.
The Company continues to focus research and development on additional
Hydron(TM) super-oxygenated products, as well as other proprietary
technology-based products as determined by Management's assessment of consumer
demand. The Company's research and development efforts during 2003 continued to
strive for greater diversification among the Company's product lines by
development of new products targeted at the aging baby boomer marketplace.
Management has completed development of an acne ingredient delivery
system. The technology allows for acidic ingredients to be delivered to the
stratum corneum of skin at neutral pH (~6.8 to 7.0) where it then gradually
adjusts to match the pH of the stratum corneum below 5.5. This delivery
technique avoids the irritation and burning associated with traditional acne
ingredients that deliver ingredients at pH values as low as 2.0. The Company
filed for provisional patent protection in February 2002 with a subsequent
utility patent filed in February 2003 for the US and international markets.
In the acne market, the medicinal cure is often more irritating and
elicits more redness than the skin breakout. The new system significantly
reduces the harshness and irritation caused by most acne products currently in
7
Item 1. Business (continued)
the marketplace. This technology is being presented to potential private label
customers.
Charles Fox, a consultant and a former member of the Company's Board of
Directors from September 1997 to October 1998, leads the Company's research and
development efforts. Mr. Fox was formerly director of product development for
Warner Lambert Company's personal products division and was a former president
of the Society of Cosmetic Chemists.
Patented Technology
The Company strongly believes that technology and patent protection are
essential to providing a sound foundation for a new product. The Company was
granted a U.S. patent on its new super-oxygenation technology in November 2003.
This patent covers the process of applying a liquid containing pure oxygen
micro-bubbles to the surface of the skin such that the oxygen penetrates the
skin and oxygenates the underlying tissue. The Company has applied for
international patents in approximately 29 countries and they are in various
stages of review as of December 31, 2003. The Company expects these patent
applications to be approved over the next 12 to 18 months.
The Company was granted U.S. Patent No. 4,883,659, dated November 28,
1989, and U.S. Patent No. 5,039,516, dated August 13, 1991, which cover a stable
moisturizing emulsion containing an unusual emulsifying agent, as well as the
Hydron(TM) polymer and a unique combination of ingredients. These patents have
expiration dates of November 28, 2006 and August 13, 2008, respectively. During
1999 the Company was granted U.S. Patent No. 5,879,684 for its "Line Smoothing
Complex" formula. This product has been clinically shown to reduce fine lines
and wrinkles. The patent has an expiration date of April 11, 2017. In addition,
the Company has registered several trademarks relating to its cosmetic products.
The Company has also received patent protection for its emulsification
process in several countries to facilitate distribution and sale of these
products outside of the United States. The Hydron(TM) polymer, utilized in
cosmetic emulsions, creates a thin moisture-attracting film that is non-greasy;
is not dissolved by sebaceous oils or perspiration; does not emulsify the skin's
natural oils and humectants; and allows the skin to breathe. The film is
insoluble in water and resistant to rub-off, but can easily be removed with
cleanser and water.
The Company subsequently discovered that the Hydron(TM) emulsion system
also adjusts pH on the skin to match the pH of the stratum corneum, the skin's
surface layer. It is evident in recent skin research that the pH range of the
emulsion system is essential for contributing to the skin's natural healing
process and enzyme production responsible for rebuilding the skin's lipid
barrier. The Company filed a provisional patent application related to acid
based ingredient delivery, including acne ingredients in February 2002 with the
corresponding utility patent application and international filings in February
2003.
8
Item 1. Business (continued)
Manufacturing and Raw Materials
Hydron(TM) polymer-based products are manufactured exclusively for the
Company by independent third parties. The Company has used principally two
manufacturers of cosmetic products because of the quality of their production
and reasonable costs. To date, contract manufacturing has allowed the Company to
meet inventory requirements in a timely manner. All raw material and packaging
components for the Company's consumer and professional product lines are readily
available to the Company from a variety of sources.
The Company is not dependent on any sole manufacturer except that the
Company's ability to obtain additional supply of the Hydron(TM) polymer is
dependent on GP Strategies Corporation (formerly known as National Patent
Development Corporation) ("GPS") and its assignee, Valera Pharmaceuticals
(formerly known as Hydro-Med Sciences, Inc.) ("Valera"), which owns certain
proprietary information relating to the manufacture of the Hydron(TM) polymer.
Under the terms of an agreement with GPS, as amended and restated (the "GPS
Agreement"), GPS is obligated to supply the Company with up to 3,000 kilograms
of the Hydron(TM) polymer for so long as GPS manufactures the Hydron(TM)
polymer, and the Company is obligated to purchase its first 3,000 kilograms of
Hydron(TM) polymer from GPS. In the event GPS is unable to manufacture and
supply the Company with its requested quantity of Hydron(TM) polymer, GPS is
obligated to provide the Company with information and assistance regarding all
technology and manufacturing procedures (including know-how) possessed by GPS
and use in connection with the manufacture of the Hydron(TM) polymer.
The Company is currently negotiating certain changes in the GPS
Agreement with Valera, including the provisions relating to supply of the
Hydron(TM) polymer. Valera has advised the Company that it has disposed of the
equipment used in the manufacture of the Hydron(TM) polymer and no longer has
the in-house capability of manufacturing the Hydron(TM) polymer. The Company is
engaged in discussions with Valera regarding alternative sources for the
Hydron(TM) polymer and for changes in the royalty structure. See discussion
under "Agreement with GPS" below. Although the Company's inventory of the
Hydron(TM) polymer is sufficient to satisfy current requirements, the loss of,
or significant reduction in, a commercially suitable supply of the Hydron(TM)
polymer would have a material adverse effect on the Company and its skin care
business.
Agreement with GPS
Under the terms of the GPS Agreement, the Company has an exclusive
worldwide license to manufacture, market or use non-prescription products that
include the Hydron(TM) polymer in the consumer field, including in connection
with cosmetic products and certain personal care products, and in the oral
health field, including dentures. Under the GPS Agreement, GPS retained the
exclusive right to manufacture, sell or distribute any prescription drug or
medical device made with the Hydron(TM) polymer, other than in the oral health
field. In addition, under the GPS Agreement, the Company and GPS may each
9
Item 1. Business (continued)
manufacture, sell, and use non-prescription drug products that include the
Hydron(TM) polymer as an active ingredient that are not included in their
respective exclusive fields.
Under the GPS Agreement, GPS also licenses to the Company the trademark
Hydron(TM) for use in connection with the manufacture, marketing and use of
products using Hydron(TM) polymers as permitted under the GPS Agreement.
Under the terms of the GPS Agreement, the Company and GPS are each
required to pay to the other a royalty of five percent (5%) of their respective
net sales of Hydron(TM) polymer products, except for sales of non-prescription
drug products utilizing the Hydron(TM) polymer as an active ingredient to third
parties where the seller receives an up-front license fee, royalty or similar
payment where the seller shall pay the other party a royalty of twenty-five
percent (25%) of such payments. An aggregate of $127,437 was accrued and unpaid
as of December 31, 2003. This amount is adequate to cover any royalties that
might be payable through that date. For the years ended December 31, 2003, 2002,
and 2001, the Company's Statement of Operations has accrued royalty expense of
approximately $0, $0, and $86,574, respectively. No royalty expense was required
in 2003 and 2002 as the definition of applicable products was changed creating a
surplus accrual. The Company has not received any royalty payments, or been
advised of any sales that would entitle us to royalty payments.
The Company and Valera are currently in discussions to amend the GPS
Agreement to, among other things, reduce their respective obligations to make
royalty payments.
Inventory
The Company did not have any backorder of firm booked orders as of
December 31, 2003 and generally delivers its orders within two weeks of the date
orders are booked. Although the Company's business in not seasonal, orders
placed by Hydron's private label customers and television retailers fluctuate on
a monthly and quarterly basis. Orders placed by the Company's Catalog customers
are generally shipped within two business days of the placement of the order.
Most items can be produced within a 90-day period. Finished good
inventory will average between 6 - 12 months of sales. Packaging components must
be printed in larger quantities and the level of those types of items may exceed
12 months sales. The inventory level of the Hydron(TM) polymer, which is unique
and comes from a single source, exceeds several years and it is stored in two
locations to ensure availability.
Government Regulation
The Company's Oxygenation process uses pure oxygen, which is a natural
substance and is not controlled. However the containers, devices used, and the
handling of oxygen require the Food and Drug Administration's approval (FDA).
The Company complies with the Federal Food, Drug and Cosmetic Act ("FDC Act")
and must comply with the labeling requirements of the FDC Act, the Fair
10
Item 1. Business (continued)
Packaging and Labeling Act ("FPL Act"), and the regulations thereunder. Many
products and applications that are derived from Hydron's oxygenation technology
will be considered medical in nature and FDA approval will be required for this
area. New skin care products and most of the Company's existing products are
"cosmetics" as that term is defined under the FDC Act. Some of the Company's
products (i.e. its topical analgesic and products that contain a sunscreen or
Triclosan) are also classified as over-the-counter drugs.
Additional regulatory requirements for existing products include
additional labeling requirements, registration of the manufacturer and
semi-annual update of the drug list. Management believes that it is in
compliance with these requirements and that it faces no material costs
associated with such compliance.
Competition
The skin care business is characterized by vigorous competition
throughout the world. Product recognition, quality, performance and price have
significant influence on customers' choices among competing products and brands.
Advertising, promotion, merchandising, the pace and timing of new product
introductions and line extensions also have a significant impact on the consumer
buying decisions. The Company competes against a number of marketers of skin
care products, many of which have substantially greater resources than the
Company. Although the Company is in competition with all skin care brands,
direct competition in electronic retailing and catalog sales includes; Principal
Secret, ProActiv, Physician's Advice, Susan Lucci, Signature Club A, Marilyn
Miglin, Dr. Graff, and Serious Skin Care.
Seasonality
The Company's results of operations are not subject to seasonal
fluctuations.
Employees
The Company satisfies its human resource needs utilizing an outsourcing
firm that provides all administrative services relating to payroll, personnel
and employee benefits. Management continues to hire, fire, set pay rates and
supervise its staff. This arrangement enables the Company to reduce its
administrative and benefits costs relating to employees. The Company as of
December 31, 2003 had seven full time positions.
Item 2. Properties
The Company maintains its offices at 2201 West Sample Road, Building 9,
Suite 7B, Pompano Beach, Florida 33073. The lease on this office space (3,750
square feet) expires August 31, 2004 and required a monthly rent of
approximately $5,400, including taxes and common area expenses. The Company
expects to renew the lease on a short-term basis. Other properties are available
at comparable monthly rental, if required.
11
Item 3. Legal Proceedings
The Company is not a party to, and its property is not the subject of,
any material pending legal proceedings.
Item 4. Submission of Matters to a Vote of Security Holders
No matters were submitted to a vote of security holders during the year
ended December 31, 2003.
12
PART II
Item 5. Market for Registrants Common Equity, Related Stockholder Matters and
Issuer Purchases of Equity Securities
Market Information
The Company's Common Stock is quoted on the OTC Bulletin Board, a
regulated quotation service for over-the-counter securities not listed or traded
on NASDAQ or a national securities exchange, under the symbol HTEC.OB. The
following tables indicate the high and low closing prices for the Company's
Common Stock as reported by the OTC Bulletin Board.
High Low
Closing Closing
Price Price
------- -------
2003
---------------
Fourth Quarter $ 0.80 $ 0.42
Third Quarter 0.80 0.57
Second Quarter 0.53 0.20
First Quarter 0.39 0.20
2002
---------------
Fourth Quarter $ 0.29 $ 0.20
Third Quarter 0.45 0.16
Second Quarter 0.34 0.21
First Quarter 0.39 0.25
As of January 14, 2004, there were approximately 3,935 shareholders of
record of the Company's Common Stock. The number of shareholders of record will
decline as the Company's transfer agent has notified the Company of its intent
to transfer shares, held in the name of shareholder that it has not been able to
locate, to the proper authorities in compliance with state law requirements
relating to unclaimed property.
Dividends and Dividend Policy
The Company does not contemplate paying dividends in the near-term. The
Board of Directors will determine the payment of dividends in the future in
light of conditions then existing, including the Company's earnings and
financial condition.
Recent Sales of Unregistered Securities
On December 10, 2002, the Company completed the sale in a non-broker
transaction to accredited investors of 1,750,000 units, comprised of one share
of Common Stock and one option to purchase one share of Common Stock at an
exercise price of $.20 per share for a three-year period commencing on the date
of issuance. The purchase price for each unit was $.20 resulting in gross
proceeds to the Company of $350,000.
13
Item 5. Market for Registrants Common Equity, Related Stockholder Matters and
Issuer Purchases of Equity Securities (continued)
In addition, on November 14, 2003, the Company completed the sale in a
non-brokered transaction to accredited investors of 2,230,000 units, comprised
of one share of its Common Stock and one common stock purchase warrant
exercisable for one share of Common Stock at an exercise price of $1 per share
for a five-year period commencing on the date of issuance. The purchase price
for each unit was $.50 resulting in gross proceeds to the Company of $1,105,000.
In each case, the Company did not register the sale of the units and
the component shares of Common Stock, and options and warrants or the shares of
Common Stock issuable upon exercise of the warrants and options under the
Securities Act in reliance on the exemption from registration provided by Rule
506 of Regulation D and Section 4(2) of the Securities Act.
In connection with the sales of these units, the Company agreed to
register the shares of Common Stock and the shares of Common Stock issuable upon
exercise of the warrants and options included in the units.
The Company has used the proceeds from the sales of these units
primarily for certain R&D and other expenses relating to the development of its
oxygenation technology and general working capital requirements.
Equity Compensation Plan Information
The following table summarizes share information about the Company's
equity compensation plans, including the company's Stock Option Plan ("the
Plan") and non-plan equity compensation agreements as of December 31, 2003:
Number of Securities Number of Securities
to be Issued Weighted-Average Remaining Available for
Upon Exercise of Exercise Price of Future Issuance Under
Outstanding Options, Outstanding Options, Equity Compensation
Plan Category Warrants and Rights Warrants and Rights Plans
---------------------------- -------------------- -------------------- --------------------
Equity compensation plans
approved by security holders 131,500 $ 0.76 39,600
Equity Compensation
plans not approved
by security holders 1,083,500 $ 0.31 (1)
--------------------
Total 1,215,000 $ 0.36
====================
(1) Options granted by Board of Directors subject to sharesholders approving a
stock option plan amendment and the adoption of a new plan.
14
Item 5. Market for Registrants Common Equity, Related Stockholder Matters and
Issuer Purchases of Equity Securities (continued)
Equity Compensation Plans Approved by Shareholders
The 1993 Nonemployee Director Stock Option Plan ("1993 Plan") was
adopted by the Board of Directors on December 22, 1993, approved by the
shareholders on July 19, 1994 and approved, as amended, by the shareholders on
December 17, 1997. The purpose of the 1993 Plan is to assist the Company in
attracting and retaining key directors who are responsible for continuing the
growth and success of the Company. No options were granted under the 1993 Plan
during the year ended December 31, 2003.
On November 10, 1997, the Board of Directors of the Company adopted the
1997 Nonemployee Director Stock Option Plan ("1997 Plan"). This plan was
approved by the shareholders on December 17, 1997. The purpose of the 1997 Plan
is to assist the Company in attracting and retaining experienced and
knowledgeable nonemployee directors who will continue to work for the best
interests of the Company.
The 1997 Plan provides nonqualified stock options for nonemployee
directors to purchase an aggregate of 100,000 shares of Common Stock, with
grants of options to purchase 2,000 shares to each nonemployee director on
October 1, 1997, grants of options to purchase 2,000 shares on each May 1st
thereafter (starting in 1999), and grants of options to purchase 2,000 shares
upon election or appointment of any new non-employee directors. The options are
not exercisable for a one-year period and are to be granted at an exercise price
equal to the average fair market value of the Common Stock during the ten
business days preceding the day of the grant of the option.
The 1997 Plan also provides nonqualified stock options for nonemployee
directors who serve on committees of the Board of Directors. The options are not
exercisable for a one-year period and are to be granted at an exercise price
equal to the average fair market value of the Common Stock during the ten
business days preceding the day of the grant of the option. No options were
granted under this provision of the 1997 Plan during the year ended December 31,
2003.
Equity Compensation Plans Not Approved by Shareholders
During August 1999, the Company agreed to grant an option to purchase
18,000 shares of the Company's common stock to each of the five individuals
comprising the Board of Directors, subject to shareholders' approval at the next
annual meeting at an exercise price of $.64065 per share. Since the options have
been granted pending shareholders' approval, the options are reflected as
outstanding as of December 31, 2000.
In August 2001, the Company agreed to increase the options granted to
Board members each year. Subject to shareholders approval, the Company agreed to
grant option to purchase a total of 20,000 shares of the Company's common stock
to each of the five individuals comprising the Board of Director, beginning with
the calendar year 2000. Subject to shareholders approval, each Board Member will
receive options to purchase 18,000 shares of common stock at an exercise price
of $.20157 for their service in 2000 and options to purchase 20,000 shares of
common stock at an exercise price of $.4275 for their service in 2001, $.3155
15
Item 5. Market for Registrants Common Equity, Related Stockholder Matters and
Issuer Purchases of Equity Securities (continued)
for their services in 2002, and $.2430 for their services in 2003. Since the
plan has not been amended by the shareholders and there are insufficient options
available in the current plan, the 2002 and 2003 options have not been reflected
as being outstanding as of December 31, 2003.
Item 6. Selected Financial Data
Years Ended December 31,
-----------------------------------------------------------------------
2003 2002 2001 2000 1999
----------- ----------- ----------- ----------- -----------
Net Sales $ 1,219,710 $ 1,671,641 $ 2,132,717 $ 2,203,847 $ 2,665,513
Operating (Loss) (835,294) (905,868) (748,243) (946,771) (3,064,189)
Interest (expense) - net (101,562) 1,028 9,198 20,945 80,860
Net (Loss) (936,856) (904,840) (758,696) (923,632) (2,974,142)
Basic & Diluted Earnings
(Loss) per Common Share (0.13) (0.17) (0.15) (0.19) (0.60)
Total Assets 1,743,087 1,468,549 2,036,182 2,800,515 3,835,303
Total Shareholders' Equity 1,168,500 887,606 1,382,944 2,141,640 3,065,272
Item 7. Management's Discussions and Analysis of Financial Condition and
Results of Operations
Overview
In November 2003 the Company was granted a patent on its new
oxygenation technology that provides a method for delivery of oxygen into the
skin and tissue at depths that are considered medically therapeutic without the
use of the blood steam. Preliminary research was conducted at the University of
Massachusetts and Florida Atlantic University and the process to obtain FDA
approval was initiated. Management plans to research additional medical
indications once Hydron obtains FDA approval.
The Company raised $1.1 million in December 2003 in a non-brokered
private placement exempt from registration under the Securities Act to fund the
initial research and initiate the lengthy FDA approval process. As research
results begin to quantify the broad applications of this technology and the FDA
hurdles are passed, Management anticipates that Hydron will attract key
strategic partners and new investment money will become available. Management
also anticipates that product development will accelerate in medical areas such
as wound and burn treatment as well as in skin care areas such as scar
reduction, acne, diaper rash, oral health, etc.
In 2002 the Company virtually eliminated sales made through television
retailers as the result of terminating the exclusive relationship with HSN in
late 2001 and as revenues derived from resales by QVC to prior customers
declined. Management expects that in 2004 and beyond, an increasing portion of
its skin care sales will be generated from direct marketing by the Company
through use of direct response mail, catalog print and sales made on its web
16
Item 7. Management's Discussions and Analysis of Financial Condition and
Results of Operations (continued)
site. Management also expects that the Company will generate an increasing
portion of its revenues from sales made through private label customers and will
look for other opportunities to sell the Company's products through similar
arrangements. Management anticipates introducing new cosmetic products based on
its oxygenation technology, which it believes will open doors for new
distribution. However, the types and timing of the introduction of new cosmetic
products will depend upon, the results of further clinical testing.
Management believes that the Company's survival and success is
dependent upon its ability to attract additional capital to complete the
commercial development of its oxygenation technology. In order to attract this
capital, Management believes that the Company's oxygenation research will need
to continue to yield results indicating the commercial viability of products
based on this technology, as well as receipt of necessary FDA approvals for
commercial medical applications of oxygenation products. In addition, Management
believes that it will be necessary for the Company to develop new products based
on its Hydron(TM) polymer, enhance retail distribution of its current products
through its proprietary catalog and web site, as well as through expansion of
third party licensing arrangements to companies that will sell the Company's
products under private labels and international distributors.
Results of Operations - 2003 versus 2002
Total net sales for 2003 were $1,219,710, a decrease of $451,931 or
27.0% from net sales of $1,671,641 for the year ended December 31, 2002. Skin
care products net sales for 2003 were $1,071,819, a decrease of $426,565 or
28.5% from sales of $1,498,384 in 2002. Professional products' net sales for
2003 were $18,067, a decrease of $12,041 or 40.0% from sales of $30,108 in 2002.
Freight revenues for 2003 were $129,823, a decrease of $13,325 of 9.3% from
freight revenues of $143,149 in 2002.
Skin care products primarily consist of catalog sales and private label
sales. During 2003, direct marketing catalog sales decreased by $164,499 or
14.3% from $1,146,989 in 2002 to $982,490 in 2003. The Company did not promote
to historical customer lists from QVC and HSN as it did in 2002. These
activities were part of the termination agreements that expired in 2002. As a
result, the promotional costs as well as the sales dollars were below those seen
in 2002. Private label sales in 2003 were $57,056, a decrease of $74,152 or
56.5% from such sales of $131,208 in 2002. These sales tend to fluctuate from
year to year as purchase orders cover more than one year's supply and every
product in the line is not purchased every year. In addition, new product
introductions are not necessarily made by the private label customers every
year. A new product was introduced in 2002, but not in 2003. Sales to retail
stores were less than 1% of sales in 2003. Retail store sales decreased $194,584
or 96.8% from $201,010 in 2002 to $6,426 in 2003, primarily reflecting minimal
follow-up orders by retail stores after heavily discounted introductory offers
in 2002.
Professional sales consist of dental products sold to dental labs for
use in manufacturing dentures. As noted above, net sales of dental products for
2003 were $18,067, a decrease of $12,041 or 40.0% from sales of $30,108 in 2002.
17
Item 7. Management's Discussions and Analysis of Financial Condition and
Results of Operations (continued)
In 2002 our customers increased their backroom stock after Hydron had delays in
filling orders in 2002 when one of the required components was discontinued.
Sales in 2003 reflect a more normal buying pattern for our existing customers
Over 98% of the Company's products are sold in the United States. The
Company sells skin care products in Australia and dental products in Spain and
Canada. These sales are not material at this time and represented 1.2% and 1.7%
of total sales for 2003 and 2002, respectively.
Cost of sales was $585,186 for 2003, a decrease of $178,172 or 23.3%
from cost of sales of $763,358 for 2002. Cost of sales was 48.0% of total sales
in 2003 compared to 45.7% in 2002. The increase in the cost of sales percentage
reflects the cost ($8,475) incurred to replace private label products that had
not sealed properly and slightly higher inventory valuation adjustments, offset
by the fact that high margin catalog sales represented a larger portion of total
sales in 2003 (80.5%) than they did in 2002 (68.5%). Cost of sales for private
label sales was in direct proportion to the sales level after taking into affect
the charge for the replacement products. The Company monitors its inventory
levels closely and writes-down any inventory in excess of one-year supply. Cost
of sales include charges of $156,762 in 2003 to adjust inventories to one-year
supply valued at the lower of cost or realizable value on a FIFO basis. Similar
charges for 2002 were $128,893. Cost increases are not material to catalog sales
and the private label contracts provide for a pass through of any cost increases
incurred in that segment.
The Company's overall gross profit margin decreased slightly to 52.0%
of net sales for 2003 versus 54.3% for 2002. This reflects the costs discussed
above less the relative mix of higher margin catalog sales versus lower margin
private label sales.
Royalty expenses in 2003 and 2002 were $0. No accrued royalty expenses
were required as the definition of applicable products was changed creating a
surplus accrual. An aggregate of $127,437 was accrued and unpaid as of December
31, 2003. This amount is adequate to cover any royalties that might be payable
through December 2003.
Research and development ("R&D") expenses reflect the Company's efforts
to identify new product opportunities, develop and package the products for
commercial sale, perform appropriate efficacy and safety tests, and conduct
consumer panel studies and focus groups. R&D expenses in 2003 were $98,568, an
increase of $30,311, or 44.4% from R&D expenses of $68,257 in 2002. This
increase is principally due to the Company's R&D work on its new oxygenation
technology. The amount of R&D expenses per year varies, depending on the nature
of the development work during each year, as well as the number and type of
products under development at such time.
Selling, general and administrative ("SG&A") expenses in 2003 were
$1,178,211, representing a decrease of $251,959 or 17.6% from SG&A expenses of
$1,430,170 in 2002. Sales commissions for 2003 were $1,816, a decrease of
$55,385 or 96.8% from $57,201 in 2002. Sales commissions were primarily related
to retails sale introductions in 2002 and decreased in line with the lower
18
Item 7. Management's Discussions and Analysis of Financial Condition and
Results of Operations (continued)
retail sales in 2003. Legal expenses were $63,504 in 2003, a decrease of $65,983
or 51.0% from the $129,487 incurred in 2002. The legal costs for 2002 included
the one-time cost associated with the Life International Products, Inc.
licensing agreement for machine technology that creates micro-bubbles in liquids
and legal costs associated with the Company's new oxygenation technology.
Payroll expense was $444,193 in 2003, a decrease of $45,647 of 9.3% from
$489,840 in 2002. This decrease was primarily due to the elimination of a
managerial position in order to control operating costs. Warehousing expense was
$37,210 in 2003, a decrease of $27,857 or 42.8% from the $65,067 incurred in
2002. This decrease reflects Management's efforts to reduce inventory levels and
streamline the product line. Promotion expense in 2003 was $52,129, a decrease
of $25,205 or 32.6% from $77,334 in 2002. This decrease was principally the
elimination of direct marketing activities to historical QVC and HSN customers.
Postage expense was $74,977 in 2003, a decrease of $14,973 of 16.6% from $89,950
in 2002. This decrease was principally the postage cost associated with the
marketing activities to QVC and HSN customers. All other expenses were $504,382
for 2003 and decreased $16,909 of 3.2% from $521,291 in 2002.
Depreciation and amortization expense was $193,039 for 2003, a decrease
of $122,685 or 38.9% from $315,724 in 2002. The decrease was primarily due to
intangible assets becoming fully amortized by mid-2003. Fully amortized
intangible assets of $5,370,000 were written off in 2003.
Net interest expense was $101,562 in 2003 compared to net interest
income of $1,028 in 2002. Interest expense for 2003 included $102,500 that
represented the fair value of stock options granted under an interest-free
bridge loan obtained from two Company Directors. The Company maintains a
conservative investment strategy with respect to its cash balances, deriving
investment income primarily from U.S. Treasury securities.
The Company had a net loss of $936,856, representing an increase of
$32,016 or 3.5% from the net loss of $904,840 for 2002, primarily a result of
the factors discussed above.
Results of Operations - 2002 versus 2001
Total net sales for 2002 were $1,671,641, a decrease of $461,076 or
21.6%, from net sales of $2,132,717 for the year ended December 31, 2001. Skin
care products net sales for 2002 were $1,498,384, a decrease of $467,743 or
23.8% from $1,966,127 in 2001. Professional products net sales for 2002 were
$30,108, an increase of $10,922 or 56.9% from $19,186 in 2001. Freight revenues
for 2002 were $143,149, a decrease of $4,255 or 2.9% from freight revenues of
$147,404 in 2001.
Skin care products consist of catalog sales, television retail, and
private label sales. During 2002, direct marketing catalog sales decreased
slightly by $31,263 or 2.6% from $1,178,252 in 2001 to $1,146,989 in 2002. The
reduction in catalog sales resulted primarily from an increase in sales made
with promotional discounts. Television retail sales in 2002 were $19,177, a
19
Item 7. Management's Discussions and Analysis of Financial Condition and
Results of Operations (continued)
decrease of $328,454 or 94.5% from $347,631 in 2001. The decrease in television
retail sales reflects the termination of the HSN agreement in late 2001, as well
as declining revenues received from repeat sales by QVC to prior purchasers of
the Company's products. Sales to television retailers represented 1.1% of the
Company's sales in 2002, down from 16.3% in 2001. Private label sales were
$131,208 in 2002; a reduction of $271,349 or 67.4% from sales of $402,557 in
2001, primarily the result of pipeline fill shipped to the customer in the
second half of 2001.
Professional sales consist of dental products sold to dental labs for
use in manufacturing dentures. Dental product sales in 2002 were $30,108, an
increase $10,922 or 56.9% from $19,186 in 2001. This increase was the result of
our customers increasing their backroom stock after Hydron had delays in filling
orders in 2002 when one of the required components was discontinued. It took
several months for the Company to certify a new manufacturer and qualify their
component for insertion in Hydron's dental product.
Over 97% of the Company's products are sold in the United States. The
Company sells skin care products in Australia and dental products in Spain and
Canada. In 2001, the Company also sold skin products to a pilot distributor in
Taiwan, but that business was not continued in 2002. International sales are not
material at this time and represented 1.7% and 2.5% of total sales for 2002 and
2001 respectively.
Cost of sales was $763,358 for 2002, a decrease of $179,302 or 19.0%
from cost of sales of $942,660 for 2001. Cost of sales was 45.7% of total sales
in 2002 compared to 44.2% in 2001. The increase in the cost of sales percentage
reflects an increase in the cost of shipments to our customers that was not
passed on in the customer's billings. Shipping cost in 2002 were $174,911, an
increase of $3,731 or 2.2% from $171,180 in 2001. In 2002, 81.8% of the shipping
costs were billed to customers compare to 86.1% in 2001. The Company monitors
its inventory levels closely and writes-down any inventory in excess of one-year
supply. Cost of sales include charges of $128,893 in 2002 to adjust inventories
to one-year supply valued at the lower of cost or realizable value on a LIFO
basis. Similar charges for 2001 were $154,594. Cost increases are not material
to catalog sales and the private label contracts provide for a pass through of
any cost increases incurred in that segment.
The Company's overall gross profit margin decreased slightly to 54.3%
of net sales for 2002 versus 55.8% for 2001, as the increased shipping costs
were not reflected in the customer billings. The gross profit margin of catalog
sales decreased slightly to 80.3% in 2002 from 81.9% in 2001 as the result of
the mix of products and collections sold.
Royalty expenses in 2002 were $0, representing a decrease of $86,574 or
100%, from royalty expenses of $86,574 in 2001. No royalty expense was required
in 2002 as the definition of applicable products was changed creating a surplus
accrual. An aggregate of $127,437 was accrued and unpaid as of December 31,
2002. This amount is adequate to cover any royalties that might be payable
through December 2002.
20
Item 7. Management's Discussions and Analysis of Financial Condition and
Results of Operations (continued)
R&D expenses reflect the Company's efforts to identify new product
opportunities, develop and package the products for commercial sale, perform
appropriate efficacy and safety tests, conduct consumer panel studies, and focus
groups. R&D expenses in 2002 were $68,257, an increase of $9,935 or 17.0%, from
R&D expenses of $58,322 in 2001. The amount of R&D expenses per year varies,
depending on the nature of the development work during each year, as well as the
number and type of products under development at such time.
SG&A expenses in 2002 were $1,430,170, representing a slight increase
of $2,054 or 0.1%, from SG&A expenses of $1,432,224 in 2001. Sales commissions
for 2002 were $57,201, a substantial increase of $51,079 from $6,122 in 2001.
This increase was directly related to commission paid during the Company's 2002
promotional program to introduce its product line to several retail chains.
Employee payroll and benefits were $577,435 in 2002, an increase of $41,380 or
7.7% from $536,055 in 2001. Payroll increased 5.0% and the remaining increase
reflected the escalating cost of medical benefits. Insurance expense for 2002
was $99,880, an increase of $22,674 or 29.4% from $77,206 in 2001. This increase
is directly related to the increased cost of Directors and Officers insurance.
All other SG&A expenses in 2002 were $695,654, a decrease of $117,187 or 14.4%
from $812,841 in 2001. This decrease includes reductions in royalties, legal and
audit fees, computer technology services and travel expenses.
Depreciation and amortization in 2002 was $315,724, a decrease of
$45,456 or 12.6% from $361,180 in 2001. This decrease relates to the
depreciation of the leasehold improvements associated with the Company's
previous office facility. The lease on that facility expired September 2001 and
the offices were relocated.
Interest and investment income in 2002 was $1,028, a decrease of $8,170
or 88.8%, from interest income of $9,198 in 2001, due primarily to lower cash
balances resulting from the factors discussed above. The Company maintains a
conservative investment strategy with respect to its cash balances, deriving
investment income primarily from U.S. Treasury securities.
The Company had a net loss for 2002 of $904,840, representing an
increase of $146,144 or 19.3% from the net loss of $758,696 for 2001, primarily
a result of the factors discussed above.
Results of Operations - 2001 versus 2000
Net sales for 2001 were $2,132,717; a decrease of $71,130 or 3.2%, from
net sales of $2,203,847 for the year ended December 31, 2000. Skin care products
net sales for 2001 were $1,966,127, a decrease of $105,814 or 5.1% from
$2,071,941 in 2000. Professional products net sales for 2001 were $19,186, an
increase of $9,659 or 101.4% from $9,527 in 2000. Freight revenues for 2001 were
$147,404, an increase of $25,025 or 20.4% from freight revenues of $122,379 in
2000.
21
Item 7. Management's Discussions and Analysis of Financial Condition and
Results of Operations (continued)
Skin care products consist of catalog sales, private label, television
retail, and international sales. During 2001, direct marketing catalog sales
were $1,178,252, an increase of $151,184 or 14.7%, from $1,027,068 in 2000. The
increase in direct marketing catalog sales resulted primarily from an increase
in new customer trial and the continuation of promotional offers to existing
customers. Private label sales in 2001 were $402,557. There were no private
label sales in 2000. Television retail sales were $347,631 in 2001, a decrease
of $697,242 or 66.7%, from $1,044,873 in 2000. The decrease in sales to
television retailers HSN and QVC primarily reflect the limited airtime provided
by HSN during the first nine months of the year and the termination of the
exclusive sales agreement with HSN, as well as declining revenues received from
resales by QVC to prior purchasers of the Company's products. Sales to
television retailers represented 16.3% of the Company's sales in 2001, down from
47.4% in 2000. In 2001, the Company had initial sales of $33,355 to a new
distributor in Taiwan. This is an introductory effort to determine if this new
distributor and the Hydron products can impact the skin care market in Taiwan.
Professional sales consist of dental products sold to dental labs for
use in manufacturing dentures. Dental product sales in 2001 were $19,186, an
increase of $9,659 or 101.4% from $9,527 in 2000.
Over 97% of the Company's products are sold in the United States. The
Company sells skin care products in Australia and dental products in Spain and
Canada. In 2001, skin care products were also sold in Taiwan. International
sales are not material at this time and represented 2.5% and 1.5% of total sales
in 2001 and 2000 respectively.
Cost of sales was $942,660 for 2001, an increase of $370,777 or 64.8%
from $571,883 in 2000. Cost of sales was 44.2% of total sales in 2001 compared
to 25.9% in 2000. The increase in 2001 reflects a shift of sales away from high
margin television retail sales (61.1%) with high promotional costs to private
label sales that have lower margins (38.1%) and minimal promotional costs. In
addition, cost of sales in 2000 reflected a one-time savings of $175,000 when a
packaging contract was favorably renegotiated. The Company monitors its
inventory levels closely and writes-down any inventory in excess of one-year
supply. Cost of sales include charges of $154,594 in 2001 to adjust inventories
to one-year supply valued at the lower of cost or realizable value on a LIFO
basis. There were no similar charges for 2000. Cost increases are not material
to catalog sales and the private label contracts provide for a pass through of
any cost increases incurred in that segment.
As a result of the above factors, the Company's overall gross profit
margin decreased to 55.8% of net sales for 2001 versus 74.1% for 2000.
Royalty expenses in 2001 were $86,574, representing a decrease of
$16,984 or 16.4%, from royalty expenses of $103,558 in 2000. The decrease in
2001 is commensurate with the decrease in gross sales derived from Hydron(TM)
polymer-based products by the Company. These expenses are related entirely to
the Company's obligations under the GPS Agreement with Hydro-Med and pertain to
22
Item 7. Management's Discussions and Analysis of Financial Condition and
Results of Operations (continued)
the use of the Hydron(TM) polymers as a formula ingredient for many of the
Company's products.
R&D expenses reflect the Company's efforts to identify new product
opportunities, develop and package the products for commercial sale, perform
appropriate efficacy and safety tests, conduct consumer panel studies, and focus
groups. R&D expenses in 2001 were $58,322, a decrease of $25,786 or 30.7%, from
R&D expenses of $84,108 in 2000. The amount of R&D expenses per year varies,
depending on the nature of the development work during each year, as well as the
number and type of products under development at such time.
SG&A expenses in 2001 were $1,432,224, representing a decrease of
$495,709 or 25.7%, from SG&A expenses of $1,927,933 in 2000. This decrease is
the result of: 1) lower marketing expenses associated with reducing activity
with HSN in 2001 ($254,618), 2) reduced selling and advertising expenses
associated with Catalog sales ($126,162), 3) reduced expenses related to outside
consultants ($84,963), and 4) reduced expenses for rents resulting from the
switch over to outside warehousing ($48,952). These cost reductions were
partially offset by: 1) increased catalog postage and handling associated with
attracting new customers ($22,217), and 2) increased legal expenses associated
with developing patents and contracts for new technology ($34,454).
The Company operated 2001 at a close-to-break-even cash flow rate
($23,879) while carefully investing in the future. Excluding some one-time
charges, 2001 would have a positive cash flow of $157,628. During the year,
there have been a number of one-time expenses that reduced operating cash,
including: costs associated with a patent application ($58,572), legal costs
associated with research and development technology ($84,718), and moving costs
associated with the relocation of the corporate offices to Pompano Beach
($38,217).
Interest and investment income in 2001 was $9,198, a decrease of
$11,746 or 56%, from interest income of $20,945 in 2000, due primarily to lower
cash balances resulting from the factors discussed above. The Company maintains
a conservative investment strategy with respect to its cash balances, deriving
investment income primarily from U.S. Treasury securities.
The Company had a net loss for 2001 of $758,696, representing a
reduction of $164,935 or 18% from the net loss of $923,631 for 2000, primarily
as a result of the significant reductions in expenses, particularly relating to
SG&A as discussed above.
Liquidity and Capital Resources
The Company anticipates that present working capital balances and
internally generated funds will be sufficient to meet our working capital needs
for the next twelve months. The development of our oxygenation technology will
depend on our ability to raise capital on commercially reasonable terms. The
Company's working capital was approximately $954,781 at December 31, 2003,
including cash and cash equivalents of approximately $964,723. Cash used by
23
Item 7. Management's Discussions and Analysis of Financial Condition and
Results of Operations (continued)
operating activities was $383,106 and $53,110 was invested in equipment and
patents. This was offset by proceeds from financing activities of $1,109,803.
The Company does not have any material debt, long-term capital leases
or long-term operating leases. The Lease on the current office facility expires
August 31, 2004 and the Company expects to renew the lease on a short-term
basis. The only capital lease expires February 4, 2005 with the total remaining
payments after December 31, 2003 of $5,006. There are no capital expenditures
under construction and no long-term commitments other than royalty payments
under an agreement with GP Strategies Corporation (See note 5 to Financial
Statements). The Company does not have any lines of credit. There are no
purchase order commitments that exceed 90 days.
The Company completed a non-brokered private placement of 1,750,000
Units at $.20 per Unit ($350,000), on December 10, 2002 to several accredited
investors. Each Unit is comprised of one share of common stock and one
three-year option to buy one additional common share at $.20. As of December 31,
2003 all 1,750,000 options are outstanding.
On November 14, 2003, the Company completed a non-brokered private
placement of 2,210,000 Units at $.50 per Unit ($1,105,000) to accredited
investors. Each Unit is comprised of one share of Common Stock and one five-year
warrant to buy one additional Common Share at $1.00. As of December 31, 2003,
all 2,210,000 warrants are outstanding.
The Company is in the process of registering these outstanding shares
and the 4,481,500 underlying shares of outstanding warrants/options with the
Securities and Exchange Commission as required by the November 14, 2003 private
placement agreement. The warrants/options are a future source of capital for the
Company and could generate up to $2,560,000 if they are exercised.
The Company's independent accountants issued a "going concern" opinion
since the Company has incurred significant losses over the past five years and
generates a negative cash flow on a monthly basis. The ability of the Company to
continue as a going concern is dependent upon increasing sales, managing
operating expenses and obtaining additional equity financing.
Management's plan includes the following elements:
o Obtaining FDA approval of the Company's oxygenation technology in
marketing segments, which are attractive to today's investor.
o Effectively applying the Company's existing resources to achieve
objectives that will attract the interest of new investors and
strategic partners.
24
Item 7. Management's Discussions and Analysis of Financial Condition and
Results of Operations (continued)
o Advancing the oxygenation technology in the medical segment that will
stimulate the interest of new investors and strategic partners.
o Entering into joint ventures with strategic partners that can provide
complimentary products, distribution, and manufacturing capabilities.
o Expanding the product line of existing private label customers and thus
leverage the Hydron(TM) polymer technology across multiple product
lines.
o Developing new skin care products for new private label customers
utilizing Hydron's proprietary expertise on a broader base of products.
o Licensing proprietary and possibly patentable technologies, including
skin and tissue oxygenation and the acne ingredient delivery system,
where appropriate to third party companies.
o Continued emphasis on catalog sales, including sales made over the
internet, since these sales have higher profit margins.
o Increased use of direct marketing techniques to reach new and current
consumers such as print promotions mailed to targeted consumers, Web
site specials, promotions to other Web site customers, and direct
E-mail promotions to new customers.
o Addition of new revenue streams through expanded international
distribution achieved through the use of distribution agreements with
foreign and international distributors.
o Development, acquisition and marketing of new product lines based on
proprietary technologies that appeal to the aging baby boomers as well
as the new generation.
o The Company will continue to develop proprietary technology that it
believes will improve its long-term success in the skin care business,
such as the acne ingredient delivery system. The Company's
super-oxygenated fluid and composition technology should allow
significant advances in skin care products and open application and
licensing opportunities beyond the skin care category.
o The Company does not have the financial resources to sustain a national
advertising campaign to support distribution of its products in
conventional retail stores. In view of the foregoing, Management's
strategy has been to enter into marketing, licensing and distribution
agreements with third parties which have greater financial and
distribution resources than those of the Company and that can enhance
the Company's product introductions with appropriate national marketing
support programs.
25
Item 7. Management's Discussions and Analysis of Financial Condition and
Results of Operations (continued)
There can be no assurances that Management's Plan will be successful
and the Company's actual results could differ materially. No estimate has been
made should Management's plan be unsuccessful.
Change in Accounting Principle and New Accounting Pronouncements
In December 2002, the FASB issued SFAS No. 148, "Accounting for
Stock-Based Compensation - Transition and Disclosure" - an amendment of FASB
Statement No. 123 "Accounting and Disclosure of Stock-Based Compensation". SFAS
No. 148 amends SFAS No. 123 to provide alternative methods of transition for a
voluntary change to the fair value based method of accounting for stock-based
employee compensation. In addition, SFAS No.148 amends the disclosure
requirements of SFAS No. 123 to require prominent disclosures in both annual
interim financial statements about the method of accounting for stock-based
employee compensation and the effect of the method used on reported results. The
disclosure requirements of SFAS No. 148 have been implemented in Note 1 and Note
10 to the accompanying financial statements, and the interim reporting
requirements were adopted in the first interim period in 2003. We have not
determined whether we will undertake a change to the fair value method in the
near future. As our supplemental disclosure in Note 1 and Note 10 indicates, our
adoption of the fair value provisions of SFAS No. 123 would not have a negative
effect on our Income Statements.
In January 2003, the FASB issued FASB Interpretation No. 46 ("FIN 46"),
"Consolidation of Variable Interest Entities, an Interpretation of ARB No. 51,"
FIN 46 requires certain variable interest entities to be consolidated by the
primary beneficiary of the entity if the equity investors in the entity do not
have the characteristics of a controlling financial interest or do not have
sufficient equity at risk for the entity to finance its activities without
additional subordinated financial support from other parties. FIN 46 is
effective immediately for all new variable interest entities created or acquired
after January 31, 2003. For variable interest entities created or acquired prior
to February 1, 2003, the provisions of FIN 46 must be applied for the first
interim or annual period beginning after June 15, 2003. The adoption of FIN 46
did not have a material impact on the Company's financial position or on its
results of operations.
In May 2003, the FASB issued SFAS No. 150, "Accounting for Certain
Financial Instruments with Characteristics of both Liabilities and Equity." SFAS
150 requires that certain financial instruments, which under previous guidance
were accounted for as equity, must now be accounted for as liabilities. The
financial instruments affected include mandatorily redeemable stock, certain
financial instruments that require or may require the issuer to buy back some of
its shares in exchange for cash or other assets and certain obligations that can
be settled with shares of stock. SFAS 150 is effective for all financial
instruments entered into or modified after May 31, 2003. Otherwise it will
become effective at the beginning of the first interim period beginning after
June 15, 2003. The Company does not anticipate that the adoption of this
statement will have any material impact on the balance sheet or statement of
operations.
26
Item 7. Management's Discussions and Analysis of Financial Condition and
Results of Operations (continued)
Shipping and handling billings and costs have been reclassified in the
2002 and 2001 financial statements to conform to the 2003 financial statement
presentation and the provisions of Emerging Issues Task Force No. 00 -10,
"Accounting for Shipping and Handling Fees and Costs". These reclassifications
have no effect on reported net income. In 2002 and 2001, the Company
reclassified $143,149 and $147,404 respectively, of shipping fees to net sales
and $174,911 and $171,180, respectively to cost of sales. Selling, general and
administrative expenses were reduced accordingly.
The effect of inflation has not been significant upon either the
operations or financial condition of the Company.
Cautionary Statement Regarding Forward Looking Statements
The statements contained in this Report on Form 10-K that are not
purely historical are forward looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934, including statements regarding the Company's expectations, hopes,
intentions, beliefs or strategies regarding the future, including, without
limitation, it's plans regarding distribution and marketing of it's products and
the development, acquisition and marketing of new products. Forward looking
statements include the Company's liquidity, anticipated cash needs and
availability, and the anticipated expense levels under the heading "Management's
Discussion and Analysis of Financial Condition and Results of Operations." All
forward looking statements included in this document are based on information
available to the Company on the date of this Report, and the Company assumes no
obligation to update any such forward looking statement. It is important to note
that the Company's actual results could differ materially from those expressed
or implied in such forward-looking statements.
Application of Critical Accounting Estimates
The preparation of financial statements requires us to make estimates
and judgments that affect the reported amounts of assets, liabilities, sales and
expenses, and related disclosure of contingent assets and liabilities. On an
ongoing basis, we evaluate our estimates, including those related to bad debts,
inventories, investments, intangible assets, income taxes, restructuring, and
contingencies and litigation. We base our estimates on historical experience and
on various other assumptions that we believe to be reasonable under the
circumstances, the results of which form the basis for making judgments about
the carrying values of assets and liabilities that are not readily apparent from
other sources. Actual results may differ from these estimates under different
assumptions or conditions.
We believe the following critical accounting estimates are significant
in preparation of our financial statements.
27
Item 7. Management's Discussions and Analysis of Financial Condition and
Results of Operations (continued)
Allowance for Sales Returns
Hydron(TM) records product sales when persuasive evidence of an
arrangement exists, shipment has occurred, the price to the buyer is fixed or
determinable and collectibility is reasonably assured. Catalog sales are sold on
a cash basis with a 30-day guarantee. Returns have been less than $10,000
annually for the last five years. A provision is made at the time sales are
recognized for the estimated cost of product warranties. Private label sales are
sold on account and are collected in 30 to 45 days. If there is a production or
packaging problem, the Company would correct the problem and replace the product
sold. To minimize that possibility, the Company inspects all production batches
before they are packaged to insure quality, effectiveness and consistency.
Inventory Valuation
Shifting sales from one item in our product line to another or minimum
production requirements may create a situation where inventory levels of
specific items may exceed the annual sales of that item. This can create
inventory levels in excess of net realizable value. We regularly review
inventory quantities on hand and, where necessary, record provisions for excess
and obsolete inventory based on either our estimated forecast of product demand
or historical usage of the product. If our sales do not materialize as planned
or decline below historic levels, we increase our reserve for excess (quantities
in excess of one year's sales) and obsolete inventory. This would reduce our
earnings and cash flows.
Packaging changes are planned far in advance in order to limit the
impact of out-dated or obsolete components. Private label customers are required
to prepay the cost of packaging materials in order to take advantage of volume
discounts and protect the Company from any sudden packaging changes.
Item 7A. Quantitative and Qualitative Disclosure About Market Risk
The Company does not have any exposure to market risk since it does not
engage in any activities with derivative financial instruments, other financial
instruments, or derivative commodity instruments, other than the temporary
investment of available cash in U.S. Treasury instruments, cash, and cash
equivalent instruments having a similar risk profile.
Item 8. Financial Statements and Supplementary Data
The Financial Statements of the Company are contained in this report
following Item 14.
28
Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure
None.
Item 9A. Controls and Procedures
As of the end of the period covered by this annual report (the
"Evaluation Date"), the Company has carried out an evaluation, under the
supervision and with the participation of management, including its Chief
Operating Officer and Chief Financial Officer, of the effectiveness of the
design and operation of the Company's disclosure controls and procedures
pursuant to SEC Rule 13a-15(b) under the Securities Exchange Act of 1934, as
amended (the "Exchange Act"). Based upon that evaluation, the Chief Operating
Officer and Chief Financial Officer concluded that the Company's disclosure
controls and procedures (as defined in SEC Rule 13a-15(e) are effective as of
the Evaluation Date.
There have been no significant changes in the Company's internal
controls or in other factors that could significantly affect internal controls
subsequent to the date that the Company carried out is evaluation.
Disclosure controls and procedures are controls and other procedures
that are designed to ensure that information required to be disclosed in the
Company's reports or submitted under the Exchange Act is recorded, processed,
summarized and reported, within the time period specified in the rules and
procedures required pursuant to the Exchange Act. Disclosure controls and
procedures, include, without limitation, controls and procedures designed to
ensure that information required to be disclosed in the Company's reports filed
under the Exchange Act is accumulated and communicated to management, including
the company's Chief Executive Officer and Chief Financial Officer, to allow
timely decisions regarding required disclosure.
It should be noted that any system of controls, however well designed
and operated, can provide only reasonable, and not absolute, assurance that the
objectives of the system will be met. In addition, the design of any control
system is based in part upon assumptions about the likelihood of future events
and may fail to reveal information that would require disclosure if events
deviate from the assumptions made by Management.
29
PART III
Item 10. Directors and Executive Officers of the Registrant
Identification of Directors and Executive Officers
Listed below are the directors and executive officers of the Company as of
December 31, 2003:
Name Position
---- --------
Richard Banakus Director, Chairman and Interim President
Karen Gray Director
Joshua Rochlin Director
Ronald J. Saul Director
Terrence S. McGrath Chief Operating Officer
William A. Lauby Chief Financial Officer
Business Experience
Richard Banakus, age 57, has served as a director of the Company since
June 1995 and as Interim President of the Company since September 19, 1997. From
April 1991 to the present, Mr. Banakus has been a private investor with
interests in a number of privately and publicly held companies. From July 1988
through March 1991, he was managing partner of Banyan Securities, Larkspur,
California, a securities brokerage firm that he founded.
Joshua Rochlin, age 37, has served as director for the Company since
January 2000. Mr. Rochlin joined GoAmerica, Inc., a wireless internet service
provider, in December 1999. He is currently Senior Vice President, Strategy and
Corporate Development at GoAmerica. Prior to joining GoAmerica, Mr. Rochlin was
the founder and Chief Executive Officer of MyCalendar.com, LLC from December
1998 to December 1999. He previously served as an associate for the law firm of
Rubin Baum Levin Constant & Friedman in New York City from February 1995 to
December 1998.
Karen Gray, age 45, has served as a director of the Company since
December 1997 and was a consultant to the Company on marketing and
communications matters from November 1996 to December 1999. Ms. Gray has over 17
years of management experience in marketing communications in various capacities
with various companies. From 1993 to November 1996, Ms. Gray served as Vice
President, Corporate Communications, of the Company. From June 1992 to November
1993, Ms. Gray served as President of MarCom Associates, Inc., a marketing
communications company that she founded.
Ronald J. Saul, age 56, has served as a director of the company since
January 2003. From September 1992 to the present Mr. Saul has been a financial
consultant. From October 1985 through August 1992 Mr. Saul was the Treasurer and
Vice President of National Intergroup, a multi company holding company. From
November 1970 to September 1985 Mr. Saul held various accounting and financial
positions with National Intergroup Inc. and its successor company National Steel
Corporation.
30
Item 10. Directors and Executive Officers of the Registrant (continued)
Terrence S. McGrath, age 46, has served as Chief Operating Officer of
the Company since January 2000. Mr. McGrath has 20+ years marketing, brand
management and sales experience in a diverse range of consumer goods and
cosmetic categories including Procter & Gamble Toiletries Division, Noxell,
makers of Cover Girl and Noxzema products where he specialized in new category
product development; The Isaly Klondike Company where he served as VP Marketing
for Klondike Ice Cream; and Pioneer Products, where he served as VP Marketing
and Sales for Betty Crocker licensed products.
William A. Lauby, age 60, has served as Chief Financial Officer of the
Company since March 2000. Mr. Lauby has 20+ years experience in companies that
manufacture and market consumer products including The Seven-Up Company and
Isaly Klondike Company. He held the position of Chief Financial Officer for
these companies as well as a pension & welfare organization. He is a CPA,
obtaining his experience with Ernst & Young.
Compliance with Section 16(A) of the Securities Exchange Act of 1934
The Company's officers, directors and beneficial owners of more than
10% of any class of its equity securities registered pursuant to Section 12 of
the Securities Exchange Act of 1934 ("Reporting Persons") are required under the
Act to file reports of ownership and changes in beneficial ownership of the
Company's equity securities with the Securities and Exchange Commission. Copies
of those reports must also be furnished to the Company. Based solely on a review
of the copies of reports furnished to the Company pursuant to the Act, the
Company believes that during the year ended December 31, 2003; all filing
requirements applicable to Reporting Persons were complied with, except that the
Chief Operating Officer has not filed an initial report on Form 3. He has
indicated that he will file it forth with.
Item 11. Executive Compensation
The following table sets forth information for the years ended December
31, 2003, 2002 and 2001 with respect to all compensation awarded to, earned by,
or paid to the Company's Chief Executive Officer, Chief Operating Officer and
Chief Financial Officer. None of the Company's other executive officers received
salary and bonus payments in excess of $100,000 during the year ended December
31, 2003.
31
Item 11. Executive Compensation (continued)
SUMMARY COMPENSATION TABLE
ANNUAL COMPENSATION
NAME AND PRINCIPLE OTHER ANNUAL
POSITION YEAR SALARY BONUS COMPENSATION
------------------------------- -------- ---------- --------- ----------------
Richard Banakus, Chairman 2003 $ 10,530 0
2002 $ 6,000 0
2001 $ 6,410 0
Terrence S. McGrath, COO 2003 $ 125,000 0
2002 $ 125,000 0
2001 $ 122,000 0
William A. Lauby, CFO 2003 $ 110,000 0
2002 $ 110,000 0
2001 $ 107,000 0
During 2003, the members of the Board were granted options to purchase
20,000 shares of the Company's common stock for participation on the Company's
Board of Directors and an additional 5,000 shares if they were on a Board of
Directors committee, subject to approval by the shareholders of the continuation
of the stock option plans and an increase to the number of shares available.
The following table sets forth certain information relating to option
exercises effected during the year ended December 31, 2003, and the value of
options held as of such date by the Company's Chief Executive Officer and all
other persons who were executive officers of the Company and its subsidiaries
for the year ended December 31, 2003. The Company does not have any outstanding
stock appreciation rights.
Aggregate Option Exercises for the Year Ended
December 31, 2003 and Year End Option Values
--------------------------------------------
Number of
securities underlying Value(1) of unexercised
unexercised options In-the-money options
at December 31, 2003 at December 31, 2003
Name Shares Acquired Value ($) Exercisable/ Exercisable/
On Exercise Realized(2) Unexercisable Unexercisable
----------- ----------- ------------- --------------
Richard Banakus -0- -0- 1,696,500(3) $1,017,985/-0-
--------------------
(1) Total value of unexercised options is based upon the closing price ($0.73)
of Common Stock as reported by NASDAQ on December 31, 2003.
(2) Value realized in dollars is the amount that the shareholder is deemed to
have received as the result of the exercise of options, based upon the
difference between the fair market value of the Common Stock as reported
by NASDAQ on the date of exercise and the exercise price of the options.
(3) Includes 1,250,000 unexercised options purchased in the Company's private
placement completed December 10, 2002; 200,000 unexercised warrants
purchased in the Company's Private Placement completed November 13, 2003;
and 125,000 options received in a bridge loan agreement with the Company
dated August 4, 2003; and 121,500 options received through the Company's
1993 Stock Option Plan.
32
Item 11. Executive Compensation (continued)
The Board of Directors has approved the issuance of an additional
178,500 options to Chairman, Richard Banakus, 425,000 options to COO, Terrence
S. McGrath and 225,000 options to CFO, William A. Lauby; subject to the approval
of a stock option plan amendment at the next shareholders' meeting. These
options have not been reflected as of December 31, 2003 calculations since there
are insufficient options available without the shareholders actions.
Employment Agreement
There were no employment contracts in 2003, 2002, and 2001.
Compensation of Directors
Employees of the Company who also serve as directors are not entitled
to any additional compensation for such service, except for Mr. Richard Banakus,
Chairman of the Board, because of his status as Interim President. The Company
does not have a written employment agreement with Mr. Banakus.
Nonemployee directors and Mr. Banakus receive an annual fee of $5,000,
accrued quarterly. During 2003, each of Messrs. Richard Banakus, Karen Gray,
Joshua Rochlin, and Ronald J. Saul earned $5,000 for their service as a
director. As of December 31, 2003, unpaid director fees total approximately
$65,000.
Item 12. Security Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters
The following table sets forth information as of December 31, 2003
regarding (i) the share ownership of the Company by each person who is known to
the Company to be the record or beneficial owner of more than five percent (5%)
of the Common Stock, (ii) the share ownership of each director of the Company,
(iii) the Chief Executive Officer of the Company and each other most highly paid
executive officer of the Company who earned in excess of $100,000 during the
year ended December 31, 2003, and (iv) the share ownership of the Company of all
directors and executive officers of the Company, as a group (six persons).
33
Item 12. Security Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters (continued)
Name and Address of Amount and Nature of Approximate
Beneficial Owner Beneficial Ownership Percent of Class
------------------------------- -------------------- ----------------
Richard Banakus 3,486,500(4) 31.8%
82 Verissimo Drive
Novato, CA 94947
Karen Gray 63,000(5) Less than 1%
P.O. Box 478
Cutchogue, NY 11935
Joshua Rochlin 40,000(6) Less than 1%
1365 Milford Terrace
Teaneck, NJ 07666
Ronald J. Saul 1,223,500(7) 12.5%
3999 Benden Drive
Murrysville PA 15668
William A. Lauby 1,000 Less than 1%
4256 SW 92 Avenue
Davie, FL 33328
All directors and executive
officers as a group (6 persons) 4,814,000(8) 41.5%
--------------------
(4) Consists of 1,790,000 shares held directly and 1,696,500 shares issuable
upon exercise of options and warrants.
(5) Consists of 3,000 shares held directly and 60,000 shares issuable upon
exercise of options.
(6) Consists of 40,000 shares issuable upon exercise of options.
(7) Consists of 673,500 shares held directly and 550,000 shares issuable upon
exercise of options and warrants.
(8) Consists of 2,467,500 shares held directly and 2,346,500 shares issuable
upon exercise of options.
Item 13. Certain Relationships and Related Transactions
No applicable transactions.
34
Item 14. Principle Accountant Fees and Services
The following table sets forth the aggregate fees billed by the
Company's principal accountant, DaszkalBolton LLP.
2003 2002
---------- ----------
Audit fees $ 40,199 $ 48,103
Audit-related fees -- --
Tax fees (Tax compliance and planning) 7,000 5,450
All ther fees -- --
---------- ----------
$ 47,199 $ 53,553
========== ==========
Under the procedures of the Company's audit committee, prior to
engagement of the Company's auditors to provide audit services and non-audit
services, the audit committee considers whether the provisions of such services
would be compatible with maintaining the independence of the Company's principal
accountants, and has determined that the provision of such services is
compatible with such accountants' independence.
35
PART IV
Item 15. Exhibits, Financial Statement Schedules and reports on Form 8-K
(a)(1) Financial Statements
The following financial statements required by Item 8 follow Item 14 of this
Report:
Page
Reports of Independent Certified Public Accountants 39
Financial Statements:
Balance Sheets
December 31, 2003 and 2002 40
Statements of Operations
Years ended December 31, 2003, 2002, and 2001 41
Statements of Changes in Shareholders'
Equity for the Years ended December 31, 2003, 2002, and 2001 42
Statements of Cash Flow
Years ended December 31, 2003, 2002, and 2001 43
Notes to Financial Statements 44 - 57
(a)(2) All financial schedules are omitted since the required information is not
present, is not in significant amounts sufficient to require submission of the
schedules or because the information required is included in the Financial
Statements or notes thereto.
36
Item 15. Exhibits, Financial Statement Schedules and reports on Form 8-K
(continued)
(a)(3) Exhibits
3.1 Restated Certificate of Incorporation of Dento-Med Industries, Inc.
("Dento-Med"), as filed with the Secretary of State of New York on March
4, 1981.(9)
3.2 Certificate of Amendment of the Certificate of Incorporation of Dento-Med
as filed with the Secretary of State of New York on September 7, 1984.(10)
3.3 By-laws of the Company, as amended March 17, 1988.(11)
3.4 Certificate of Change of Dento-Med as filed with the Secretary of State of
New York on July 14, 1988.(10)
3.5 Certificate of Amendment of the Restated Certificate of Incorporation of
Dento-Med, as filed with the Secretary of State of New York on November
14, 1988.(12)
3.6 Certificate of Amendment of the Restated Certificate of Incorporation of
Dento-Med, as filed with the Secretary of State of New York on July 30,
1993.(13)
3.7 Certificate of Amendment of the Restated Certificate of Incorporation of
Hydron Technologies, Inc., as filed with the Secretary of State of New
York on April 10, 2002.(10)
4.1 Non-Qualified Stock Option Plan.(14)
4.2 Registration Rights Agreement dated July 11, 2002, by and between Hydron
Technologies, Inc. and Life International Products, Inc.(10)
4.3 Warrant Agreement dated November 14, 2003 between Hydron Technologies,
Inc. and the parties named therein.(10)
10.1 Subscription Agreement dated November 22, 2002 between Hydron
Technologies, Inc. and the subscribers named therein.(10)
10.2 Subscription Agreement dated September 31, 2003 between Hydron
Technologies, Inc. and the subscribers named therein.(10)
10.3 Agreement dated July 11, 2002 between Hydron Technologies, Inc. and Life
International Products, Inc.(10)
10.4 1997 Nonemployee Director Stock Option Plan.(15)
--------------------
(9) Incorporated by reference to the Company's report on Form 10-K for the
year ended December 31, 1985.
(10) Incorporated by reference to the Company's report on Form S-3 filed
February 11, 2004.
(11) Incorporated by reference to the Company's report on Form 10-K for the
year ended December 31, 1987.
(12) Incorporated by reference to the Company's report on Form 10-K for the
year ended December 31, 1988.
(13) Incorporated by reference to the Company's report on Form 10-K for the
year ended December 31, 1993.
(14) Incorporated by reference to the Company's report on Form 10-K for the
year ended December 31, 1986.
(15) Incorporated by reference to the Company's Definitive Proxy Statement on
Schedule 14A for the year ended December 31, 1996.
37
Item 15. Exhibits, Financial Statement Schedules and reports on Form 8-K
(continued)
10.5 Bridge Loan Term Sheet for Interim Loans Between Hydron Technologies, Inc
and Members of the Board of Directors.(10)
(b) Reports on Form 8-K
None.
--------------------
(10) Incorporated by reference to the Company's report on Form S-3 filed
February 11, 2004.
38
Report of Independent Certified Public Accountants
The Board of Directors and Shareholders
Hydron Technologies, Inc.
We have audited the accompanying balance sheets of Hydron Technologies, Inc. as
of December 31, 2003 and 2002 and the related statements of operations, changes
in shareholders' equity and cash flows for the years ended December 31, 2003,
2002, and 2001. These financial statements are the responsibility of the
Company's Management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates
made by Management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our
opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Hydron(TM) Technologies, Inc.
at December 31, 2003, 2002, and 2001, and the results of its operations and its
cash flows for the years then ended, in conformity with accounting principles
generally accepted in the United States.
The accompanying financial statements have been prepared assuming the Company
will continue as a going concern. The Company experienced losses from operations
in 2003, 2002, and 2001. These matters raise substantial doubt about the
Company's ability to continue as a going concern. Management has implemented
direct marketing techniques to increase the more profitable catalog sales, add
new customers and take advantage of new channels of distribution (see Note 11 to
Financial Statements). The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
/s/ DaszkalBolton LLP
Boca Raton, Florida
March 31, 2004
39
HYDRON TECHNOLOGIES, INC.
Balance Sheets
December 31,
----------------------------
ASSETS 2003 2002
------------ ------------
Current assets
Cash and cash equivalents $ 964,723 $ 291,136
Trade accounts receivable 10,191 40,000
Inventories 520,032 742,529
Prepaid expenses and other current assets 34,422 40,007
------------ ------------
Total current assets 1,529,368 1,113,672
Property and equipment, less accumulated
depreciation of $204,361 and $552,459 at
2003 and 2002, respectively 17,641 9,448
Deposits 19,587 20,816
Deferred product costs, less accumulated
amortization of $133,186 and $5,317,262 at
2003 and 2002, respectively 176,491 324,613
------------ ------------
Total Assets $ 1,743,087 $ 1,468,549
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
Accounts payable $ 42,229 $ 133,983
Loans payable 4,803 --
Royalties payable 127,437 127,437
Deferred revenues 165,164 96,390
Accrued liabilities 234,954 223,133
------------ ------------
Total current liabilities 574,587 580,943
Commitments and contingencies -- --
Shareholders' equity
Preferred stock - $.01 par value
5,000,000 shares authorized; no shares issued
or outstanding -- --
Common stock - $.01 par value
30,000,000 shares authorized; 9,320,336 shares
issued and 9,260,136 shares outstanding at 2003;
7,110,336 shares issued and 7,050,136 shares
outstanding at 2002 93,203 71,103
Additional paid-in capital 21,086,237 19,890,587
Accumulated deficit (19,571,782) (18,634,926)
Treasury stock, at cost; 60,200 shares at 2003 and 2002 (439,158) (439,158)
------------ ------------
Total Shareholders' equity 1,168,500 887,606
------------ ------------
Total liabilities and shareholders equity $ 1,743,087 $ 1,468,549
============ ============
See accompanying notes to financial statements
40
HYDRON TECHNOLOGIES, INC.
Statement of Operations
Year ended December 31,
-----------------------------------------
2003 2002 2001
----------- ----------- -----------
Net sales $ 1,219,710 $ 1,671,641 $ 2,132,717
Cost of sales 585,186 763,358 942,660
----------- ----------- -----------
Gross profits 634,524 908,283 1,190,057
Expenses
Royalty expense -- -- 86,574
Research and development 98,568 68,257 58,322
Selling, general & administration 1,178,211 1,430,170 1,432,224
Depreciation & amortization 193,039 315,724 361,180
----------- ----------- -----------
Total expenses 1,469,818 1,814,151 1,938,300
----------- ----------- -----------
Operating loss (835,294) (905,868) (748,243)
Interest (expense)income - net (101,562) 1,028 9,198
Loss on abandonment of lease -- -- (19,651)
----------- ----------- -----------
Loss before income taxes (936,856) (904,840) (758,696)
Income taxes expense -- -- --
----------- ----------- -----------
Net loss $ (936,856) $ (904,840) $ (758,696)
=========== =========== ===========
Basic and diluted loss per share
Net loss per common share $ (0.13) $ (0.17) $ (0.15)
=========== =========== ===========
Weighted average shares
outstanding (basic and diluted) 7,340,766 5,201,369 4,975,136
=========== =========== ===========
See accompanying notes to financial statements
41
HYDRON TECHNOLOGIES, INC.
Statement of Shareholders' Equity
Common Stock Preferred Stock Additional Treasury
---------------------- ----------------- Paid-in Accumulated Stock Total
Shares Amount Shares Amount Capital Deficit (at cost) Equity
---------- --------- ------- ------- ------------ ------------ ------------ ------------
Balance at December 31, 2000 5,035,336 $ 50,353 -- -- $ 19,501,837 $(16,971,390) $ (439,158) $ 2,141,642
Net loss -- -- -- -- -- (758,696) -- (758,696)
---------- --------- ------- ------- ------------ ------------ ------------ ------------
Balance at December 31, 2001 5,035,336 50,353 -- -- 19,501,837 (17,730,086) (439,158) 1,382,946
Issuance of Common shares
for license agreement 325,000 3,250 -- -- 52,000 -- -- 55,250
Private placement of
common shares 1,750,000 17,500 -- -- 332,500 -- -- 350,000
Compensation expense from
stock option awards -- -- -- -- 4,250 -- -- 4,250
Net loss -- -- -- -- -- (904,840) -- (904,840)
---------- --------- ------- ------- ------------ ------------ ------------ ------------
Balance at December 31, 2002 7,110,336 71,103 -- -- 19,890,587 (18,634,926) (439,158) 887,606
Private placement of
common shares 2,210,000 22,100 -- -- 1,082,900 -- -- 1,105,000
Compensation expense from
stock option awards -- -- -- -- 112,750 -- -- 112,750
Net loss -- -- -- -- -- (936,856) -- (936,856)
---------- --------- ------- ------- ------------ ------------ ------------ ------------
Balance at December 31, 2003 9,320,336 $ 93,203 -- -- $ 21,086,237 $(19,571,782) $ (439,158) $ 1,168,500
========== ========= ======= ======= ============ ============ ============ ============
See accompanying notes to financial statements.
42
HYDRON TECHNOLOGIES, INC.
Statements of Cash Flow
Year ended December 31,
-----------------------------------------
2003 2002 2001
----------- ----------- -----------
Operating activities
Net loss $ (936,856) $ (904,840) $ (758,696)
Adjustments to reconcile net loss to
net cash used by operating activities
Depreciation and amortization 193,039 315,724 361,180
Loss on disposal of assets -- -- 19,651
Compensation expense from stock option awards 11,188 4,250 --
Interest expense from stock optins awarded 101,562 -- --
Change in operating assets and liabilities
Trade accounts receivables 29,809 21,444 74,862
Inventories 222,497 421,768 325,099
Prepaid expenses and other current assets 5,585 3,443 (3,831)
Deposits 1,229 7,386 32,198
Accounts payable (91,754) 17,424 (78,232)
Deferred revenues 68,774 (52,256) 148,646
Accrued liabilities 11,821 (37,460) (76,051)
----------- ----------- -----------
Net cash provided (used) by operating activities (383,106) (203,117) 44,826
Investing activities
Capital expenditures (15,308) -- (10,133)
Deferred product costs (37,802) (22,814) (58,572)
----------- ----------- -----------
Net cash provided (used) by investing activities (53,110) (22,814) (68,705)
Financing activities
Proceeds from bridge loan 250,000 -- --
Repayment of bridge loan (250,000) -- --
Proceeds from Common Stock private placements of 2,210,000
and 1,750,00 shares in 2003 and 2002, respectively 1,105,000 350,000 --
Net cash provided from new loans payable 4,803 -- --
----------- ----------- -----------
Net cash provided (used) by financing activities 1,109,803 350,000 --
----------- ----------- -----------
Net increase (decrease) in cash and cash equivalents 673,587 124,069 (23,879)
Cash and cash equivalents at beginning of period 291,136 167,067 190,946
----------- ----------- -----------
Cash and cash equivalents at end of period $ 964,723 $ 291,136 $ 167,067
=========== =========== ===========
Noncash investing and financing activities
Market value of stock issued for license agreement $ -- $ 55,250 $ --
See accompanying notes to financial statements
43
Hydron Technologies, Inc.
Notes to Financial Statements
December 31, 2003, 2002, and 2001
1. Description of Business and Summary of Significant Accounting Policies
Organization of Business
Hydron(TM) Technologies, Inc. (the "Company") sells consumer and
professional products, primarily in the personal care/cosmetics field. The
Company holds the exclusive license with National Patent Development Corporation
("National Patent") to a Hydron(TM) polymer-based drug delivery system for
topically applied, nonprescription pharmaceutical products, which the Company
intends to use to develop proprietary products or license to third parties. The
Company owns U.S. and international patents on a method to suspend the
Hydron(TM) polymer in a stable emulsion for use in personal care/cosmetic
products.
The Company is also committed to the research and development of
products and medical applications associated with its proprietary tissue
oxygenation technology. The Company owns U.S. and international patents on a
method to infuse oxygen into the skin and tissue topically without using the
blood stream. The oxygenation technology is being submitted to the Food & Drug
Administration to obtain the necessary approvals for medical applications.
Over 98% of the Company's products are sold in the United States
directly to the consumer through Catalog sales and the internet, and to private
label customers. Less than 2% of the Company's products are sold internationally
through salons and doctors offices.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires Management to make estimates and
assumptions that affect the amounts reported in the financial statements and
accompanying notes. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments with an original
maturity of three months or less to be cash equivalents. The credit risk
associated with cash equivalents is considered low due to the credit quality of
the issuers of the financial instruments.
Cash and cash equivalents includes $5,026 which are covered by the
Federal Deposit Insurance Commission and $959,198 is invested in short-term
money market funds consisting of U.S. Government instruments.
44
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
1. Description of Business and Summary of Significant Accounting Policies
(continued)
Concentration of Credit Risk
Trade accounts receivable are due primarily from Reliv International,
Inc. and are usually paid to the Company within 30 days after receipt of goods.
The Company performs ongoing evaluations of its significant customers and does
not require collateral, although in some cases it requires deposits or advances.
Inventories
Inventories are valued at the lower of cost (first-in, first-out) or
market, and include finished goods, packaging and raw materials.
Long-Lived Assets
Hydron reviews long-lived assets and certain identifiable intangibles
held and used for possible impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be
recoverable. In evaluating the fair value and future benefits of its intangible
assets, Management performs an analysis of the anticipated undiscounted future
net cash flows of the individual assets over the remaining amortization period.
Hydron recognizes an impairment loss if the carrying value of the asset exceeds
the expected future cash flows. As of December 31, 2003 there was no deemed
impairment of long-lived assets.
Property and Equipment
Property and equipment, consisting primarily of furniture and
equipment, is carried at cost. Depreciation is computed using the straight-line
method over the estimated useful lives of the assets, ranging from four to six
years (see Note 4).
Deferred Product Costs
Deferred product costs consist primarily of costs incurred for the
purchase and development of patents and product rights (see Note 5). The
deferred product costs are being amortized over their estimated useful lives of
five to seventeen years using the straight-line method.
Common Stock, Common Stock Options and Net Loss Per Share
When the Company issues shares of common stock in exchange for
services, an expense is recognized over the period in which the services are
rendered. The expense is based upon the fair value of such shares, in accordance
with FASB statement No. 123 using a Black-Scholes pricing model, at the date
such arrangements are consummated or authorized by the Board of Directors, with
a corresponding credit to capital.
45
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
1. Description of Business and Summary of Significant Accounting Policies
(continued)
The Company has elected to follow Accounting Principles Board (APB)
Opinion No. 25, "Accounting for Stock Issued to Employees," and related
Interpretations in accounting for its stock options and has adopted the
disclosure-only provisions of FASB Statement No. 123, "Accounting and Disclosure
of Stock-Based Compensation." Accordingly, no compensation cost has been
recognized for the Company's stock option plans.
In December 2002, the Financial Accounting Standards Board issued
Statement of Financial Accounting Standards No. 148, "Accounting for Stock-Based
Compensation-Transition and Disclosure." The Company has elected to use the
intrinsic value method of accounting for stock compensation in accordance with
APB No. 25 and related interpretations. Had the compensation expense for the
stock option plan been determined based on the fair value of the options at the
grant date consistent with the methodology prescribed under Statement of
Financial Standards No. 123, "Accounting for Stock Based Compensation," at
December 31, the Company's net income and earnings per share would have been
reduced to the proforma amounts indicated below:
Year ended December 31,
-----------------------------------------
2003 2002 2001
----------- ----------- -----------
Net income, as reported $ (936,856) $ (904,840) $ (758,696)
Deduct: Total stock-based employee
compensation expense determined
under fair value-based method for all
awards, net of related tax effects $ -- $ (12,500) $ --
----------- ----------- -----------
Pro Forma net income $ (936,856) $ (917,340) $ (758,696)
=========== =========== ===========
Basic and diluted loss per share
As reported $ (0.13) $ (0.17) $ (0.15)
=========== =========== ===========
Pro forma $ (0.13) $ (0.18) $ (0.15)
=========== =========== ===========
46
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
1. Description of Business and Summary of Significant Accounting Policies
(continued)
Revenue Recognition
The Company recognizes revenue when
o Persuasive evidence of an arrangement exists
o Shipment has occurred
o Price is fixed or determinable, and
o Collectibility is reasonably assured
Subject to these criteria, the Company recognizes revenue at the time
of shipment of the relevant merchandise. The Company offers its customers a
thirty-day warranty and estimates an allowance for sales returns based on
historical experience with product returns.
Shipping and Handling Fees
The Company follows the provisions of Emerging Issues Task Force Issue
No. 00-10, "Accounting for Shipping and Handling Fees and Costs." Any amounts
billed to third-party customers for shipping and handling is included as a
component of revenue. Shipping and handling costs incurred are included as a
component of cost of sales.
Cost of Sales
Products are manufactured through third parties under contract and cost
of sales includes the cost of ingredients, packaging material, assembly and
processing costs. Inbound freight, internal transfers, and component handling
costs are charged to cost of sales. Costs associated with shipping product to
customers is included in cost of sales. The cost of warehousing finished product
that is available for sale is included in selling, general and administrative
expenses.
Advertising
Advertising costs are expensed as incurred and are included in
"selling, general and administrative expenses." Advertising expenses amounted to
approximately $52,000, $72,000, and $77,000, for 2003, 2002, and 2001,
respectively.
Reclassifications
Shipping and handling billings and costs have been reclassified in the
2002 and 2001 financial statements to conform to the 2003 financial statement
presentation and the provisions of Emerging Issues Task Force No. 00 -10,
"Accounting for Shipping and Handling Fees and Costs". These reclassifications
have no effect on reported net income. In 2002 and 2001, the Company
reclassified $143,149 and $147,404 respectively, of shipping fees to Net sales
and $174,911 and $171,180, respectively, of shipping costs to cost of sales.
Selling, general and administrative expenses were reduced accordingly.
47
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
2. Fair Value of Financial Instruments
The carrying value of cash, accounts receivables, deposits, accounts
payable, and other payables approximates fair value because of their short
maturities.
3. Inventories
At December 31, 2003 and 2002, inventories consist of the following:
2003 2002
---------- ----------
Finished goods $ 90,443 $ 208,748
Raw materials and components 429,589 533,781
---------- ----------
$ 520,032 $ 742,529
========== ==========
The Company's earnings were reduced for excess inventory by $156,762,
$128,893 and $154,594, for the years ended December 31, 2003, 2002, and 2001,
respectively.
48
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
4. Property and Equipment
At December 31, 2003 and 2002, property and equipment consisted of the
following:
2003 2002
----------- -----------
Furniture and equipment $ 222,002 $ 561,907
Less accumulated depreciation (204,361) (552,459)
----------- -----------
$ 17,641 $ 9,448
=========== ===========
Depreciation for the year ended December 31, 2003, 2002, and 2001 was
approximately $7,115, $17,926 and $74,111 respectively.
5. Deferred Product Costs and Royalty Agreements
From 1976 through 1989, the Company and GP Strategies Corporation
(formerly known as National Patent Development Corporation) ("GPS") entered into
various agreements, wherein the Company obtained the exclusive worldwide rights
to market products using Hydron(TM) polymers in the consumer and oral health
fields, the two fields in which the Company has concentrated its research and
development efforts, and to utilize the Hydron(TM) polymer as a drug release
mechanism in topically applied, nonprescription pharmaceutical products. The
Hydron(TM) polymer is the underlying technology in substantially all of the
Company's skin care products. GPS has the exclusive worldwide license to market
prescription drugs and medical devices using Hydron(TM) polymers. Further, each
has the right to exploit products with Hydron(TM) polymers not in the other's
exclusive fields. As consideration for product rights obtained, the Company
issued GPS an aggregate of 220,000 shares of common stock through 1989, valued
at $5,370,000. The valuation for these shares was based on the market prices of
the Company's common stock at the dates the agreements were made.
At December 31, 2003 and 2002 deferred product costs consisted of the
following:
2003 2002
----------- -----------
Deferred product cost $ 309,677 $ 271,875
Patent cost -- 5,370,000
----------- -----------
309,677 5,641,875
Less accumulated amoritization (133,186) (5,317,262)
----------- -----------
$ 176,491 $ 324,613
=========== ===========
49
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
5. Deferred Product Costs and Royalty Agreements (continued)
Deferred product costs are written off in the year they are fully
amortized. Fully amortized deferred product cost of $5,370,00 and $462,557 were
written off in 2003 and 2002, respectively. Amortization for the year ended
December 31, 2003, 2002, and 2001 was approximately $185,924, $297,798 and
$287,069 respectively. Estimated future amortization of intangible assets are as
follows:
2004 $ 25,985
2005 25,985
2006 25,985
2007 14,935
2008 11,388
thereafter 72,215
Under the terms of the GPS Agreement, the Company and GPS are each
required to pay to the other a royalty of five percent (5%) of their respective
net sales of Hydron(TM) polymer products, except for sales of non-prescription
drug products utilizing the Hydron(TM) polymer as an active ingredient to third
parties where the seller receives an up-front license fee, royalty or similar
payment where the seller shall pay the other party a royalty of twenty-five
percent (25%) of such payments. An aggregate of $127,437 was accrued and unpaid
as of December 31, 2003. This amount is adequate to cover any royalties that
might be payable through December 2003. For the years ended December 31, 2003,
2002, and 2001, the Company's Statement of Operations has accrued royalty
expense of approximately $0, $0 and $87,000, respectively. No accrued royalty
expense was required in 2003 and 2002 as the definition of applicable products
was changed creating a surplus accrual. The Company has not received any royalty
payments, or been advised of any sales that would entitle us to royalty
payments.
GPS has assigned its rights under the GPS Agreement to Valera
Pharmaceuticals (formerly known as Hydro-Med Sciences, Inc.) (Valera). The
Company and Valera are currently in discussions to amend the GPS Agreement to,
among other things, reduce their respective obligations to make royalty
payments. No agreement is eminent and one may not be reached.
6. Accrued Liabilities
Accrued liabilities represent expenses that apply to the reported
period and have not been billed by the provider or paid by the Company. At
December 31, 2003 and 2002, accrued liabilities consisted of the following:
50
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
6. Accrued Liabilities (continued)
2003 2002
---------- ----------
Dividends payable $ 83,163 $ 83,163
Director fee payable 65,012 50,008
Legal fees 35,552 6,687
Other 51,227 83,275
---------- ----------
$ 234,954 $ 223,133
========== ==========
7. Income Taxes
The Company accounts for income taxes under FASB Statement No. 109,
"Accounting for Income Taxes" (FASB 109). Deferred income tax assets and
liabilities are determined based upon differences between financial reporting
and tax bases of assets and liabilities and are measured using the enacted tax
rates and laws that will be in effect when the differences are expected to
reverse. There has been no income tax expense during the three years ended
December 31, 2003.
Deferred income taxes reflect the net tax effect of temporary
differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes. Significant
components of the Company's net deferred income taxes are as follows:
2003 2002 2001
----------- ----------- -----------
Net operating loss carryforwards $ 8,015,000 $ 7,890,000 $ 7,494,000
Tax credit carry forwards 180,000 180,000 180,000
Other 215,000 230,000 465,000
----------- ----------- -----------
Deferred tax assets 8,410,000 8,300,000 8,139,000
Less valuation allowance (8,410,000) (8,300,000) (8,139,000)
----------- ----------- -----------
Total net deferred taxes $ -- $ -- $ --
=========== =========== ===========
FASB 109 requires a valuation allowance to reduce the deferred tax
assets reported if, based on the weight of the evidence, it is more likely than
not that some portion or all of the deferred tax assets will not be realized.
After consideration of all the evidence, both positive and negative, Management
has determined that an $8,410,000 valuation allowance at December 31, 2003 is
necessary to reduce the deferred tax assets to the amount that will more likely
than not be realized. The valuation allowance increased by $110,000, $161,000,
and $249,000 in 2003, 2002, and 2001, respectively. At December 31, 2003, the
51
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
7. Income Taxes (continued)
Company has available net operating loss carryforwards of $21,092,000, which
will expire beginning in the year 2004 and through the year 2018.
The reconciliation of income tax rates, computed at the U.S. federal
statutory tax rates, to income tax expense is as follows:
Year ended December 31,
---------------------------------
2003 2002 2001
-------- -------- --------
Tax at U.S. statutory rates -34% -34% -34%
State income taxes, net of federal tax benefit -4% -4% -4%
Valuation allowance adjustments 38% 38% 38%
-------- -------- --------
0% 0% 0%
======== ======== ========
8. Stock Options and Warrants
The number of shares of common stock reserved for issuance was
4,521,100 for December 31, 2003 and 2,036,100 for 2002. This includes 1,750,000
and 2,210,000 shares for the private placement subscription agreements completed
December 10, 2002 and November 14, 2003.
1997 Nonemployee Director Stock Option Plan
During 1997, the Company adopted the 1997 Nonemployee Director Stock
Option Plan. Such plan provides grants of stock options to nonemployee directors
of the Company to purchase an aggregate of 100,000 shares of the Company's
common stock.
Each nonemployee director shall be granted an option to purchase 2,000
shares of the Company's common stock on each May 1st throughout the term of this
plan at exercise prices equal to the average of the fair market value of the
Company's common stock during the ten business days preceding the date of the
grant. In addition, each nonemployee director who sits on a committee of the
Board of Directors shall be granted an option to purchase 500 shares of the
Company's common stock under the same pricing arrangements as above. Subject to
certain exceptions, no options granted under this plan shall be exercisable
until one year after the date of grant.
During August 1999, the Company agreed to increase the annual May 1st
grant to the Board Members from 2,000 to 20,000 shares of the Company's common
stock, subject to shareholders' approval at the next annual meeting. Since the
options have been granted pending shareholders' approval, the options are
reflected as outstanding as of December 31, 2003. These options expire five
52
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
8. Stock Options and Warrants (continued)
years from the date of grant and all outstanding options are exercisable at
December 31, 2003. There are no options available for grant under this plan at
December 31, 2003. Activity with respect to these plans is as follows:
Weighted
Number of Average
Options/ Price Exercise
Warrants Per Share Price
---------- -------------- -------
Outstanding at December 31, 2001 206,500 $0.37 to $3.53 $ 0.96
Stock options granted 81,000 0.20 to 0.43 0.32
Stock options expired (64,000) 0.31 to 3.53 1.34
----------
Outstanding at December 31, 2002 223,500 0.20 to 2.42 0.62
Stock options granted -- -- --
Stock options expired (2,000) 2.42 2.42
----------
Outstanding at December 31, 2003 221,500 0.20 to 0.92 0.56
==========
The Board of Directors has approved the issuance of an additional
943,500 options subject to the approval of a stock option plan amendment or the
adoption of a new plan at the next shareholders' meeting. These options have not
been reflected as of December 31, 2003 calculations since there are insufficient
options available without the shareholders' actions.
Other Options and Warrants
The Company completed a non-brokered private placement of 1,750,000
Units at $.20 per Unit ($350,000), on December 10, 2002 to several accredited
investors. Each Unit is comprised of one share of common stock and one
three-year option to buy one additional common share at $.20. As of December 31,
2003 all 1,750,000 options are outstanding.
On November 14, 2003, the Company completed a non-brokered private
placement of 2,210,000 Units at $.50 per Unit ($1,105,000) to accredited
investors. Each Unit is comprised of one share of Common Stock and one five-year
warrant to buy one additional Common Share at $1.00. As of December 31, 2003,
all 2,210,000 warrants are outstanding.
The Company has agreements with several consultants who are to provide
financial, business and technical advice to the Company in connection with the
research, development, marketing and promotion of its products and other
53
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
8. Stock Options and Warrants (continued)
matters. In exchange, these consultants were granted warrants and nonqualified
stock options to purchase shares of the Company's common stock at prices
representing the fair market value of the shares at the date of grant. Activity
with respect to options and warrants granted to these consultants is summarized
below:
Weighted
Number of Average
Options Price Exercise
Warrants Per Share Price
---------- -------------- -------
Outstanding at December 31, 2001 -- $ -- $ --
Stock options granted 25,000 0.22 0.22
----------
Outstanding at December 31, 2002 25,000 0.22 0.22
Stock options granted 25,000 0.50 0.50
----------
Outstanding at December 31, 2003 50,000 $ 0.22 to 0.50 $ 0.36
==========
The Company's Statement of Operations for the year ended December 31,
2003 includes $102,500 of interest expense representing the fair value of
options granted in order to obtain an interest-free bridge loan from two of the
Company's Directors. An additional $10,250 is included in Selling, general &
administrative expenses representing the fair value of options granted for
services received in the private placement offering that closed on November 13,
2003. For the year ended December 31, 2003, research and development cost
included $4,250 representing the fair value of option granted to the Company's
technical consultant.
Pro forma information regarding net income and earnings per share is
required by FASB Statement No. 123, which also requires that the information be
determined as if the Company had accounted for its stock options granted
subsequent to December 31, 1994 under the fair value method of that Statement.
The fair value for these options was estimated at the date of the grant using a
Black-Scholes option pricing model with the following weighted-average
assumptions for the years ended December 31, 2003, 2002, and 2001:
54
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
8. Stock Options and Warrants (continued)
2003 2002 2001
-------- -------- --------
Risk-free interest rate 4.0% 4.5% *
Expected life 5 years 5 Years *
Expected volatility 139% 159% *
Expected dividend yield 0% 0% *
* No options were granted in 2001
The Black-Scholes option valuation model was developed for use in
estimating the fair value of traded options, which have no vesting restrictions
and are fully transferable. In addition, option valuation models require the
input of highly subjective assumptions including the expected stock price
volatility. Since the Company's stock options have characteristics significantly
different than those of traded options, and because changes in the subjective
input assumptions can materially affect the fair value estimate, in Management's
opinion, the existing models do not necessarily provide a reliable single
measure of the fair value of its stock options.
There were no options granted during the year ended December 31, 2003
and 2002. The weighted average remaining contractual life of all options
outstanding at December 31, 2003 was 4.6 years.
9. Commitments
The Company leases office space under a non-cancelable lease agreement,
which expires in August 2004. At December 31, 2003, the future minimum rental
payments due under this noncancelable lease are $43,400 for the year ending
December 31, 2004. Net rent expense was approximately $65,300, $70,000, and
$74,900 in 2003, 2002, and 2001, respectively.
The Company has purchased computer equipment through a financing lease
that expires in February 2005. At December 31, 2003, the future minimum lease
payments due under this non-cancelable lease are $4,621 and $770 for the year
ended December 31, 2004 and 2005.
55
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
10. Quarterly Financial Data (unaudited)
For the year ended December 31, 2003
-------------------------------------------------
First Second Third Fourth
Quarter Quarter Quarter Quarter
---------- ---------- ---------- ----------
Net sales* $ 314,243 $ 322,100 $ 325,405 $ 257,962
Operating income (loss) (208,100) (157,898) (162,979) (306,317)
Net income (loss) (207,712) (157,675) (163,572) (407,897)
Income (loss) per share $ (0.03) $ (0.02) $ (0.02) $ (0.06)
* Restated to include billings for shipping fees previously recorded net of
shipping costs in selling, general and administrative expenses.
11. Management's Plan
The Company has incurred significant losses over the past five years
and generates a negative cash flow on a monthly basis. The ability of the
Company to continue as a going concern is dependent upon increasing sales,
managing operating expenses and obtaining additional equity financing.
Management's plan includes the following elements:
o Obtaining FDA approval of the Company's oxygenation technology in
marketing segments, which are attractive to today's investor.
o Effectively applying the Company's existing resources against
objectives that will attract the interest of new investors and
strategic partners.
o Advancing the oxygenation technology in the medical segment that will
stimulate the interest of new investors and strategic partners.
o Creating joint ventures with strategic partners that can provide
complimentary products.
o Expanding the product line of existing private label customers and thus
leverage the Hydron technology across multiple product lines.
o Developing new skin care products for new private label customers
utilizing Hydron's proprietary expertise on a broader base of products.
56
Hydron Technologies, Inc.
Notes to Financial Statements (continued)
11. Management's Plan (continued)
o Licensing proprietary and possibly patentable technologies, including
skin and tissue oxygenation and the acne ingredient delivery system,
where appropriate to third party companies.
o Continued emphasis on Catalog sales, including sales made over the
internet, since these sales have higher profit margins.
o Increased use of direct marketing techniques to reach new and current
consumers such as print promotions mailed to targeted consumers, Web
site specials, promotions to other Web site customers, and direct
E-mail promotions to new customers.
o Addition of new revenue streams through expanded international
distribution achieved through the use of distribution agreements with
foreign and international distributors.
o Development, acquisition and marketing of new product lines based on
proprietary technologies that appeal to the aging baby boomers as well
as the new generation.
o The Company will continue to develop proprietary technology that it
believes will improve its long-term success in the skin care business,
such as the acne ingredient delivery system. The Company's
Super-oxygenated fluid and composition technology should allow
significant advances in skin care products and open application and
licensing opportunities beyond the skin care category.
o The Company does not have the financial resources to sustain a national
advertising campaign to support distribution of its products in
conventional retail stores. In view of the foregoing, Management's
strategy has been to enter into marketing, licensing and distribution
agreements with third parties which have greater financial and
distribution resources than those of the Company and that can enhance
the Company's product introductions with appropriate national marketing
support programs.
There can be no assurances that Management's Plan will be successful
and the Company's actual results could differ materially. No estimate has been
made should Management's plan be unsuccessful.
57
[LOGO DaszkalBolton LLP]
----------------------------
CERTIFIED PUBLIC ACCOUNTANTS
Michael I. Daszkal, CPA, P.A. 2401 N.W. Boca Raton Blvd
Jeffrey A. Bolton, CPA, P.A. Boca Raton, FL 33433
Timothy R. Devlin, CPA, P.A. t: 561.367.1040
Michael S. Kridel, CPA, P.A. f: 561.750.3236
Marjorie A. Horwin, CPA, P.A. www.daszkalbolton.com
CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANT
--------------------------------------------------
We hereby consent to the incorporation by reference in the Registration
Statements (Forms S-8 Nos. 33-78296, 33-84554, and 33-11765) of Hydron
Technologies, Inc. and the related prospectuses of our audit report dated March
18, 2004 with respect to the balance sheets at December 31, 2003 and 2002 and
statements of operations, changes in shareholder' equity and cash flows of
Hydron Technologies, Inc. for the years ended December 31, 2003, 2002 and 2001
in the Form 10-K.
/s/ DASZKAL BOLTON LLP
Boca Raton, Florida
April 12, 2004
58
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Hydron Technologies, Inc.
(Registrant)
By: /s/ RICHARD BANAKUS
------------------------------------
Richard Banakus, Interim President
Date: April 12, 2004
Pursuant to the requirements of the Securities Exchange Act of 1934,
this Report has been signed below by the following persons on behalf of the
Registrant in the capacities and on the dates indicated:
59